

2 Incidence and mortality

Introduction

Classifications

Recent *Cancer in Australia* reports have been based on the International Classification of Diseases for Oncology, 2nd edition (ICD-O-2) classification scheme for cancers (WHO 1990). This is the first report based on the third edition of the classification, the ICD-O-3 scheme (WHO 2000). The main effects of this change are that some neoplasms that used to be considered of borderline malignancy are now considered malignant and vice versa:

- Five types of neoplasms of the ovary and two of the brain changed from malignant to borderline.
- One type of neoplasm of the cervix, two of the brain and meninges, and 10 of the lymphoid and haematopoietic system changed from borderline to malignant.

Neoplasms of borderline malignancy are not considered cancers and so their numbers are not reported here. Conditions that change from malignant to borderline pose no problem for measuring past trends or forecasting future ones because they are simply no longer counted. However, conditions that change from borderline to malignant do pose a problem because they may not have been routinely collected by cancer registries until very recently. Hence there may be no reliable historical data. This is indeed the case for the 10 types of lymphoid and haematopoietic neoplasms mentioned above. For 2003 there are complete or reasonably complete incidence data. However, for 2002 several states and territories do not have complete data and none has for 2001 and before.

In order to allow comparison of incidence (coded by cancer registries in ICD-O-3) and mortality (coded by the ABS in ICD-10) the ICD-O-3 topography and morphology codes are mapped to appropriate ICD-10 codes. However, some ICD-O-3 codes for lymphoid and haematopoietic neoplasms do not map well to ICD-10. Therefore this chapter includes a section in which the incidence of these conditions is reported using ICD-O-3 morphology codes.

Age-standardised rates

Incidence and mortality are reported using numbers and age-standardised rates (ASRs). Two different ASRs are used: ASR(A) uses the Australian 2001 Standard Population and ASR(W) uses the World 2000 Standard Population. The methods for calculating these rates are explained in Appendix B.

Non-melanocytic skin cancer

NMSC will be used throughout this report as an abbreviation for non-melanocytic skin cancer (also called non-melanoma skin cancer). By far the two most common types of NMSC are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), each of which is more

common than all other cancers combined. These two cancers are the only cancers that are not legally notifiable diseases and as such the exact numbers of these conditions are unknown. Estimates of the frequency of treated BCC and SCC are derived from data that have been collected in national household surveys in 1985, 1990, 1995 and 2002 (NCCI 2003). The 2002 survey report indicates that approximately 256,000 people were diagnosed with BCC and 118,000 with SCC in Australia during 2002, a total of 374,000 people. In contrast, the total number of all other cancers diagnosed in 2002 was 92,337.

NMSC is excluded from all further incidence data in this report.

Risk of a diagnosis of cancer

The life-expectancy of Australians in 2003–2005 was 78.5 years for males and 83.3 years for females (ABS 2006a). The cancer incidence tables in this chapter provide the risk of a diagnosis of cancer to age 75 and age 85. Note that these risks represent averages over the whole population and do not take account of any individual's risk factors.

Person-years of life lost

The cancer mortality tables in this chapter provide the total person-years of life lost (PYLL) to age 75 and age 85. PYLL measures how many years of life are lost due to premature death. A person who dies at age 10 loses many more potential years of life than a person who dies at age 90.

Estimates of cancer incidence and mortality in 2006

It is estimated that in 2006 there were 106,000 new cases of cancer diagnosed in Australia (60,600 males and 45,400 females) and 39,200 deaths from cancer (21,900 males and 17,300 females).

Background

In 2005 it was projected that, based on trends to 2001, there would be 93,332 new cases of cancer diagnosed in 2003 in Australia, 50,531 males and 42,801 females (AIHW, AACR & NCSG: Ian McDermid 2005). The actual number of cases diagnosed in 2003 was 93,194, almost the same as the total projected. However, there were about 900 additional cancers diagnosed in males, because of an increase in the incidence of prostate cancer in 2003, and about 900 fewer cancers diagnosed in females, mainly because of a decline in the incidence of breast cancer in females in 2003.

In Chapter 4 the rise in the incidence of prostate cancer is analysed in association with screening and hospitalisation data trends. It is concluded that in 2006 an estimated 18,700 new cases of prostate cancer will have been diagnosed, well above the projection of 12,929. The age-standardised incidence rate of breast cancer in females was rising slightly each year until 2001. It was projected in 2005 that the 2001 rate would continue unchanged. In fact, the rate declined from 117.2 cases per 100,000 females in 2001 to 116.8 per 100,000 in 2002 and 111.8 per 100,000 in 2003. New South Wales breast cancer numbers tend to mirror national trends. The age-standardised rate in New South Wales was 117.5 and 117.6 per 100,000 in

2001 and 2002 before declining to 114.8 per 100,000 in 2003 and to 111.9 per 100,000 in 2004 (Cancer Institute NSW 2007). It is not known whether the rate will stabilise at this lower level, decline further or actually begin to rise again with increased screening rates in response to an increased marketing effort in some states and territories to encourage greater participation in screening. Assuming that the national age-standardised rate continues at about 111 new cases per 100,000 females, the estimated number of new cases in 2006 is 12,500, compared with the 2005 projection of 13,261.

Changes have occurred in incidence for other cancers, but prostate cancer and breast cancer are two of the three most common cancers and therefore significant changes in these cancers have a larger impact on the projected numbers. In 2005 it was projected that there would be 100,976 new cases of cancer diagnosed in 2006. However, with an estimated 5,800 additional cases of prostate cancer and 761 fewer cases of female breast cancer, it is now estimated that approximately 106,000 new cases of cancer will have been diagnosed in 2006: 60,600 males and 45,400 females.

To estimate cancer deaths in 2006, age-specific death rates for males and females by 5-year age group for all cancers from 2000 to 2004 were projected to 2006 and applied to the 2006 estimated resident population. This resulted in a mortality estimate of 39,200 deaths from cancer in 2006: 21,900 males and 17,300 females.

Incidence in 2003

The 10 most common cancers are shown in Table 2.1. Incidence data on a more comprehensive list of cancers are shown in tables 2.2–2.4.

Most common cancers in 2003

- In 2003 prostate cancer (13,526 cases) overtook colorectal cancer (12,536) as Australia's most common cancer (excluding NMSC). The next most common cancers in persons were breast cancer (11,889 cases), melanoma of the skin (9,524) and lung cancer (8,249). These five cancers accounted for 60% of all new cancers.
- In males the five most common cancers were prostate cancer (13,526 cases), colorectal cancer (6,857), melanoma of the skin (5,535), lung cancer (5,281) and lymphoma (2,297). These five cancers accounted for 65% of all new cancers in males.
- In females the five most common cancers were breast cancer (11,788 cases), colorectal cancer (5,679), melanoma of the skin (3,989), lung cancer (2,968) and lymphoma (1,832). These five cancers accounted for 63% of all new cancers in females.

Risk of a diagnosis of cancer, based on 2003 data

- In 2003 the risk of a diagnosis of cancer for males was 1 in 3 before age 75 and 1 in 2 before age 85. The highest risk was for prostate cancer, with a 1 in 9 chance before age 75 and a 1 in 5 chance before age 85.
- In females the risk was 1 in 4 before age 75 and 1 in 3 before age 85. The highest risk was for breast cancer, with a 1 in 11 chance before age 75 and a 1 in 9 chance before age 85.

Table 2.1: The 10 most common cancers, Australia, 2003^(a)

Cancer type	Number	Per cent of total	ASR(A) ^(b)	ASR(W) ^(b)	Risk to age 75	Risk to age 85
Persons						
Prostate	13,526	14.5	—	—	—	—
Colorectal	12,536	13.5	61.3	43.4	1 in 22	1 in 12
Breast	11,889	12.8	—	—	—	—
Melanoma	9,524	10.2	46.9	37.1	1 in 28	1 in 19
Lung	8,249	8.9	40.4	28.2	1 in 33	1 in 17
Lymphoma	4,129	4.4	20.3	15.7	1 in 66	1 in 40
Unknown site	3,454	3.7	16.8	11.3	1 in 98	1 in 44
Leukaemia	2,524	2.7	12.4	9.8	1 in 114	1 in 66
Bladder	2,229	2.4	10.9	7.3	1 in 138	1 in 63
Kidney	2,019	2.2	9.9	7.5	1 in 126	1 in 80
<i>All cancers^(a)</i>	<i>93,194</i>	<i>100.0</i>	<i>456.8</i>	<i>339.1</i>	<i>1 in 3</i>	<i>1 in 2</i>
Males						
Prostate	13,526	26.3	144.2	101.2	1 in 9	1 in 5
Colorectal	6,857	13.3	73.2	51.6	1 in 18	1 in 10
Melanoma	5,535	10.8	57.9	44.2	1 in 24	1 in 15
Lung	5,281	10.3	57.1	38.9	1 in 25	1 in 12
Lymphoma	2,297	4.5	24.1	18.7	1 in 56	1 in 34
Unknown site	1,749	3.4	19.3	12.9	1 in 85	1 in 38
Bladder	1,649	3.2	18.3	12.0	1 in 89	1 in 38
Leukaemia	1,460	2.8	15.6	12.0	1 in 93	1 in 51
Kidney	1,302	2.5	13.6	10.1	1 in 94	1 in 57
Stomach	1,216	2.4	13.2	9.1	1 in 108	1 in 55
<i>All cancers^(a)</i>	<i>51,418</i>	<i>100.0</i>	<i>548.2</i>	<i>394.4</i>	<i>1 in 3</i>	<i>1 in 2</i>
Females						
Breast	11,788	28.2	111.8	89.0	1 in 11	1 in 9
Colorectal	5,679	13.6	51.1	36.2	1 in 27	1 in 15
Melanoma	3,989	9.5	37.9	31.0	1 in 34	1 in 25
Lung	2,968	7.1	27.1	19.3	1 in 49	1 in 27
Lymphoma	1,832	4.4	16.9	13.0	1 in 80	1 in 48
Unknown site	1,705	4.1	14.7	9.8	1 in 116	1 in 50
Uterus	1,613	3.9	15.1	11.7	1 in 74	1 in 54
Ovary	1,084	2.6	10.1	7.8	1 in 123	1 in 81
Leukaemia	1,064	2.5	9.8	7.8	1 in 144	1 in 87
Thyroid	1,041	2.5	10.2	9.0	1 in 127	1 in 113
<i>All cancers^(a)</i>	<i>41,776</i>	<i>100.0</i>	<i>386.5</i>	<i>294.8</i>	<i>1 in 4</i>	<i>1 in 3</i>

(a) Excluding non-melanocytic skin cancer (ICD-10 code C44).

(b) Age-standardised rates are expressed per 100,000 persons/males/females depending on the section of the table.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.2: Cancer incidence in persons, Australia, 2003

Cancer site/type (ICD-10 codes)	Number	Per cent of total	ASR(A)	ASR(W)	Risk to age 75	Risk to age 85	M:F ratio (ASR(A))
Lip (C00)	987	1.1	4.9	3.8	1 in 265	1 in 177	3.0
Tongue (C01–C02)	492	0.5	2.4	1.9	1 in 474	1 in 341	2.6
Mouth (C03–C06)	466	0.5	2.3	1.7	1 in 561	1 in 340	1.8
Major salivary glands (C07–C08)	229	0.2	1.1	0.8	1 in 1,210	1 in 744	1.7
Oropharynx (C09–C10)	292	0.3	1.4	1.2	1 in 770	1 in 616	4.1
Nasopharynx (C11)	107	0.1	0.5	0.5	1 in 2,350	1 in 2,041	2.7
Hypopharynx (C12–C13)	133	0.1	0.7	0.5	1 in 1,527	1 in 1,168	9.0
Pharynx, unspecified (C14)	70	0.1	0.3	0.3	1 in 3,676	1 in 2,262	4.3
Nasal cavity, middle ear & sinuses (C30–C31)	130	0.1	0.6	0.5	1 in 2,032	1 in 1,223	2.0
Larynx (C32)	557	0.6	2.7	2.1	1 in 406	1 in 281	9.4
<i>Head and neck (C01–C14, C30–C32)</i>	<i>2,476</i>	<i>2.7</i>	<i>12.1</i>	<i>9.3</i>	<i>1 in 97</i>	<i>1 in 67</i>	<i>3.1</i>
Oesophagus (C15)	1,154	1.2	5.6	3.9	1 in 256	1 in 125	2.4
Stomach (C16)	1,873	2.0	9.2	6.4	1 in 153	1 in 80	2.3
Small intestine (C17)	347	0.4	1.7	1.3	1 in 749	1 in 446	1.5
Colon (C18)	8,144	8.7	39.8	27.7	1 in 35	1 in 18	1.3
Rectum (C19–C20)	4,392	4.7	21.5	15.8	1 in 58	1 in 35	1.8
<i>Colorectal (C18–C20)</i>	<i>12,536</i>	<i>13.5</i>	<i>61.3</i>	<i>43.4</i>	<i>1 in 22</i>	<i>1 in 12</i>	<i>1.4</i>
Anus (C21)	252	0.3	1.2	0.9	1 in 1,096	1 in 691	0.8
Liver (C22)	890	1.0	4.4	3.2	1 in 300	1 in 168	2.6
Gallbladder (C23–C24)	586	0.6	2.9	2.0	1 in 515	1 in 246	0.8
Pancreas (C25)	1,996	2.1	9.7	6.6	1 in 152	1 in 73	1.4
Lung, bronchus & trachea (C33–C34)	8,249	8.9	40.4	28.2	1 in 33	1 in 17	2.1
Other thoracic organs (C37–C38)	74	0.1	0.4	0.3	1 in 3,674	1 in 2,558	2.1
Bone & articular cartilage (C40–C41)	167	0.2	0.8	0.8	1 in 1,585	1 in 1,358	1.5
Melanoma of skin (C43)	9,524	10.2	46.9	37.1	1 in 28	1 in 19	1.5
Mesothelioma (C45)	633	0.7	3.1	2.1	1 in 435	1 in 215	5.8
Kaposi sarcoma (C46)	57	0.1	0.3	0.2	1 in 3,997	1 in 3,230	7.7
Peritoneum & retroperitoneum (C48)	165	0.2	0.8	0.6	1 in 1,334	1 in 990	0.4
Other connective and soft tissue (C47, C49)	491	0.5	2.4	2.0	1 in 585	1 in 356	1.7
Breast (C50)	11,889	12.8	—	—	—	—	0.01
Vulva (C51)	220	0.2	—	—	—	—	—
Vagina (C52)	67	0.1	—	—	—	—	—
Cervix (C53)	725	0.8	—	—	—	—	—
Uterus, body (C54)	1,613	1.7	—	—	—	—	—
Uterus, unspecified (C55)	85	0.1	—	—	—	—	—

(continued)

Table 2.2 (continued): Cancer incidence in persons, Australia, 2003

Cancer site/type (ICD-10 codes)	Number	Per cent of total	ASR(A)	ASR(W)	Risk to age 75	Risk to age 85	M:F ratio (ASR(A))
Ovary (C56)	1,084	1.2	—	—	—	—	—
Other female genital organs (C57)	57	0.1	—	—	—	—	—
Placenta (C58)	6	0.0	—	—	—	—	—
<i>Gynaecological (C51–C58)</i>	<i>3,857</i>	<i>4.1</i>	<i>—</i>	<i>—</i>	<i>—</i>	<i>—</i>	<i>—</i>
Penis (C60)	67	0.1	—	—	—	—	—
Prostate (C61)	13,526	14.5	—	—	—	—	—
Testis (C62)	638	0.7	—	—	—	—	—
Other male genital organs (C63)	24	0.0	—	—	—	—	—
Kidney (C64)	2,019	2.2	9.9	7.5	1 in 126	1 in 80	2.0
Bladder (C67)	2,229	2.4	10.9	7.3	1 in 138	1 in 63	3.6
Other urinary organs (C65–C66, C68)	362	0.4	1.8	1.2	1 in 926	1 in 370	1.1
Eye (C69)	254	0.3	1.3	1.0	1 in 1,028	1 in 669	1.5
Brain (C71)	1,360	1.5	6.7	5.6	1 in 191	1 in 131	1.4
Other central nervous system (C70, C72)	71	0.1	0.4	0.3	1 in 3,760	1 in 2,722	1.2
Thyroid (C73)	1,402	1.5	7.0	6.1	1 in 187	1 in 158	0.4
Other endocrine organs (C74–C75)	76	0.1	0.4	0.4	1 in 3,391	1 in 2,527	1.3
Hodgkin lymphoma (C81)	430	0.5	2.2	2.1	1 in 615	1 in 495	1.4
Non-Hodgkin lymphoma (C82–C85, C96)	3,699	4.0	18.1	13.7	1 in 74	1 in 43	1.4
<i>All lymphomas (C81–C85, C96)</i>	<i>4,129</i>	<i>4.4</i>	<i>20.3</i>	<i>15.7</i>	<i>1 in 66</i>	<i>1 in 40</i>	<i>1.4</i>
Immunoproliferative neoplasms (C88)	86	0.1	0.4	0.3	1 in 4,423	1 in 1,545	2.0
Myeloma (C90)	1,153	1.2	5.6	3.9	1 in 257	1 in 127	1.5
Lymphoid leukaemia (C91)	1,214	1.3	6.0	4.9	1 in 230	1 in 139	1.7
Myeloid leukaemia (C92–C94)	1,238	1.3	6.1	4.6	1 in 234	1 in 133	1.5
Leukaemia, unspecified (C95)	72	0.1	0.4	0.3	1 in 4,985	1 in 2,146	1.7
<i>All leukaemias (C91–C95)</i>	<i>2,524</i>	<i>2.7</i>	<i>12.4</i>	<i>9.8</i>	<i>1 in 114</i>	<i>1 in 66</i>	<i>1.6</i>
Polycythaemia rubra vera (D45)	326	0.3	1.6	1.2	1 in 797	1 in 473	1.8
Myelodysplastic syndromes (D46)	988	1.1	4.8	3.0	1 in 471	1 in 146	2.0
Other chronic myeloproliferative diseases (D47 ^(b))	303	0.3	1.5	1.0	1 in 1,104	1 in 486	1.3
Unknown primary site (C26, C39, C76, C80)	3,454	3.7	16.8	11.3	1 in 98	1 in 44	1.3
All cancers (C00–C96^(a), D45–D47^(b))	93,194	100.0	456.8	339.1	1 in 3	1 in 2	1.4

(a) Excluding non-melanocytic skin cancer (ICD-10 code C44).

(b) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.3: Cancer incidence in males, Australia, 2003

Cancer site/type (ICD-10 codes)	Number	Per cent of total	ASR(A)	ASR(W)	Risk to age 75	Risk to age 85
Lip (C00)	717	1.4	7.4	5.9	1 in 173	1 in 116
Tongue (C01–C02)	343	0.7	3.5	2.7	1 in 314	1 in 235
Mouth (C03–C06)	287	0.6	3.0	2.2	1 in 423	1 in 271
Major salivary glands (C07–C08)	136	0.3	1.5	1.0	1 in 1,018	1 in 525
Oropharynx (C09–C10)	232	0.5	2.3	1.9	1 in 471	1 in 383
Nasopharynx (C11)	77	0.1	0.8	0.6	1 in 1,544	1 in 1,343
Hypopharynx (C12–C13)	119	0.2	1.2	0.9	1 in 839	1 in 615
Pharynx, unspecified (C14)	55	0.1	0.6	0.4	1 in 2,155	1 in 1,378
Nasal cavity, middle ear & sinuses (C30–C31)	82	0.2	0.9	0.6	1 in 1,436	1 in 895
Larynx (C32)	498	1.0	5.1	3.9	1 in 221	1 in 149
<i>Head and neck (C01–C14, C30–C32)</i>	<i>1,829</i>	<i>3.6</i>	<i>18.9</i>	<i>14.4</i>	<i>1 in 62</i>	<i>1 in 43</i>
Oesophagus (C15)	765	1.5	8.2	5.7	1 in 169	1 in 88
Stomach (C16)	1,216	2.4	13.2	9.1	1 in 108	1 in 55
Small intestine (C17)	195	0.4	2.1	1.5	1 in 620	1 in 370
Colon (C18)	4,185	8.1	45.2	31.2	1 in 31	1 in 16
Rectum (C19–C20)	2,672	5.2	28.0	20.4	1 in 44	1 in 26
<i>Colorectal (C18–C20)</i>	<i>6,857</i>	<i>13.3</i>	<i>73.2</i>	<i>51.6</i>	<i>1 in 18</i>	<i>1 in 10</i>
Anus (C21)	105	0.2	1.1	0.8	1 in 1,270	1 in 806
Liver (C22)	614	1.2	6.5	4.8	1 in 198	1 in 113
Gallbladder (C23–C24)	238	0.5	2.6	1.8	1 in 545	1 in 271
Pancreas (C25)	1,047	2.0	11.3	7.8	1 in 124	1 in 62
Lung, bronchus & trachea (C33–C34)	5,281	10.3	57.1	38.9	1 in 25	1 in 12
Other thoracic organs (C37–C38)	48	0.1	0.5	0.4	1 in 2,660	1 in 1,698
Bone & articular cartilage (C40–C41)	99	0.2	1.0	1.0	1 in 1,310	1 in 1,135
Melanoma of skin (C43)	5,535	10.8	57.9	44.2	1 in 24	1 in 15
Mesothelioma (C45)	524	1.0	5.7	3.8	1 in 252	1 in 116
Kaposi sarcoma (C46)	50	0.1	0.5	0.4	1 in 2,331	1 in 1,744
Peritoneum & retroperitoneum (C48)	41	0.1	0.4	0.3	1 in 2,465	1 in 1,991
Other connective and soft tissue (C47, C49)	296	0.6	3.1	2.5	1 in 469	1 in 259
Breast (C50)	101	0.2	1.1	0.8	1 in 1,189	1 in 722
Penis (C60)	67	0.1	0.7	0.5	1 in 2,192	1 in 987
Prostate (C61)	13,526	26.3	144.2	101.2	1 in 9	1 in 5
Testis (C62)	638	1.2	6.5	6.4	1 in 221	1 in 214
Other male genital organs (C63)	24	0.0	0.3	0.2	1 in 5,493	1 in 2,996
Kidney (C64)	1,302	2.5	13.6	10.1	1 in 94	1 in 57
Bladder (C67)	1,649	3.2	18.3	12.0	1 in 89	1 in 38
Other urinary organs (C65–C66, C68)	171	0.3	1.9	1.2	1 in 896	1 in 340
Eye (C69)	146	0.3	1.5	1.2	1 in 865	1 in 525
Brain (C71)	770	1.5	7.9	6.5	1 in 164	1 in 111
Other central nervous system (C70, C72)	38	0.1	0.4	0.3	1 in 3,774	1 in 2,183
Thyroid (C73)	361	0.7	3.7	3.1	1 in 353	1 in 261

(continued)

Table 2.3 (continued): Cancer incidence in males, Australia, 2003

Cancer site/type (ICD-10 codes)	Number	Per cent of total	ASR(A)	ASR(W)	Risk to age 75	Risk to age 85
Other endocrine organs (C74–C75)	42	0.1	0.4	0.4	1 in 3,264	1 in 2,183
Hodgkin lymphoma (C81)	247	0.5	2.5	2.4	1 in 528	1 in 424
Non-Hodgkin lymphoma (C82–C85, C96)	2,050	4.0	21.6	16.3	1 in 63	1 in 36
<i>All lymphomas (C81–C85, C96)</i>	<i>2,297</i>	<i>4.5</i>	<i>24.1</i>	<i>18.7</i>	<i>1 in 56</i>	<i>1 in 34</i>
Immunoproliferative neoplasms (C88)	52	0.1	0.6	0.4	1 in 3,337	1 in 1,139
Myeloma (C90)	637	1.2	7.0	4.7	1 in 220	1 in 103
Lymphoid leukaemia (C91)	719	1.4	7.6	6.1	1 in 184	1 in 107
Myeloid leukaemia (C92–C94)	700	1.4	7.6	5.6	1 in 198	1 in 105
Leukaemia, unspecified (C95)	41	0.1	0.4	0.3	1 in 3,987	1 in 1,606
<i>All leukaemias (C91–C95)</i>	<i>1,460</i>	<i>2.8</i>	<i>15.6</i>	<i>12.0</i>	<i>1 in 93</i>	<i>1 in 51</i>
Polycythaemia rubra vera (D45)	198	0.4	2.1	1.6	1 in 587	1 in 376
Myelodysplastic syndromes (D46)	581	1.1	6.8	4.1	1 in 354	1 in 104
Other chronic myeloproliferative diseases (D47 ^(b))	152	0.3	1.7	1.1	1 in 1,061	1 in 451
Unknown primary site (C26, C39, C76, C80)	1,749	3.4	19.3	12.9	1 in 85	1 in 38
All cancers (C00–C96^(a), D45–D47^(b))	51,418	100.0	548.2	394.4	1 in 3	1 in 2

(a) Excluding non-melanocytic skin cancer (ICD-10 code C44).

(b) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.4: Cancer incidence in females, Australia, 2003

Cancer site/type (ICD-10 codes)	Number	Per cent of total	ASR(A)	ASR(W)	Risk to age 75	Risk to age 85
Lip (C00)	270	0.6	2.5	1.8	1 in 563	1 in 337
Tongue (C01–C02)	149	0.4	1.4	1.1	1 in 937	1 in 586
Mouth (C03–C06)	179	0.4	1.6	1.2	1 in 829	1 in 448
Major salivary glands (C07–C08)	93	0.2	0.9	0.7	1 in 1,476	1 in 1,109
Oropharynx (C09–C10)	60	0.1	0.6	0.4	1 in 2,070	1 in 1,459
Nasopharynx (C11)	30	0.1	0.3	0.3	1 in 4,844	1 in 4,068
Hypopharynx (C12–C13)	14	0.0	0.1	0.1	1 in 7,536	1 in 5,813
Pharynx, unspecified (C14)	15	0.0	0.1	0.1	1 in 11,885	1 in 5,250
Nasal cavity, middle ear & sinuses (C30–C31)	48	0.1	0.4	0.3	1 in 3,367	1 in 1,819
Larynx (C32)	59	0.1	0.6	0.4	1 in 2,222	1 in 1,311
<i>Head and neck (C01–C14, C30–C32)</i>	<i>647</i>	<i>1.5</i>	<i>6.0</i>	<i>4.6</i>	<i>1 in 218</i>	<i>1 in 135</i>
Oesophagus (C15)	389	0.9	3.4	2.2	1 in 511	1 in 200
Stomach (C16)	657	1.6	5.8	4.1	1 in 254	1 in 127
Small intestine (C17)	152	0.4	1.4	1.0	1 in 936	1 in 538
Colon (C18)	3,959	9.5	35.4	24.6	1 in 39	1 in 20
Rectum (C19–C20)	1,720	4.1	15.7	11.5	1 in 84	1 in 50
<i>Colorectal (C18–C20)</i>	<i>5,679</i>	<i>13.6</i>	<i>51.1</i>	<i>36.2</i>	<i>1 in 27</i>	<i>1 in 15</i>
Anus (C21)	147	0.4	1.3	1.0	1 in 968	1 in 614
Liver (C22)	276	0.7	2.5	1.8	1 in 608	1 in 293
Gallbladder (C23–C24)	348	0.8	3.1	2.1	1 in 487	1 in 230
Pancreas (C25)	949	2.3	8.3	5.6	1 in 192	1 in 86
Lung, bronchus & trachea (C33–C34)	2,968	7.1	27.1	19.3	1 in 49	1 in 27
Other thoracic organs (C37–C38)	26	0.1	0.2	0.2	1 in 5,821	1 in 4,388
Bone & articular cartilage (C40–C41)	68	0.2	0.7	0.6	1 in 2,010	1 in 1,687
Melanoma of skin (C43)	3,989	9.5	37.9	31.0	1 in 34	1 in 25
Mesothelioma (C45)	109	0.3	1.0	0.7	1 in 1,460	1 in 724
Kaposi sarcoma (C46)	7	0.0	0.1	0.0	1 in 13,323	1 in 13,323
Peritoneum & retroperitoneum (C48)	124	0.3	1.2	0.9	1 in 922	1 in 685
Other connective and soft tissue (C47, C49)	195	0.5	1.8	1.6	1 in 767	1 in 513
Breast (C50)	11,788	28.2	111.8	89.0	1 in 11	1 in 9
Vulva (C51)	220	0.5	1.9	1.3	1 in 856	1 in 406
Vagina (C52)	67	0.2	0.6	0.4	1 in 2,715	1 in 1,343
Cervix (C53)	725	1.7	7.0	5.9	1 in 191	1 in 149
Uterus, body (C54)	1,613	3.9	15.1	11.7	1 in 74	1 in 54
Uterus, unspecified (C55)	85	0.2	0.8	0.6	1 in 1,794	1 in 1,307
Ovary (C56)	1,084	2.6	10.1	7.8	1 in 123	1 in 81
Other female genital organs (C57)	57	0.1	0.5	0.4	1 in 2,450	1 in 1,567
Placenta (C58)	6	0.0	0.1	0.1	1 in 24,334	1 in 24,334

(continued)

Table 2.4 (continued): Cancer incidence in females, Australia, 2003

Cancer site/type (ICD-10 codes)	Number	Per cent of total	ASR(A)	ASR(W)	Risk to age 75	Risk to age 85
<i>Gynaecological (C51–C58)</i>	3,857	9.2	36.2	28.3	1 in 34	1 in 24
Kidney (C64)	717	1.7	6.7	5.1	1 in 191	1 in 121
Bladder (C67)	580	1.4	5.1	3.5	1 in 299	1 in 134
Other urinary organs (C65–C66, C68)	191	0.5	1.7	1.1	1 in 958	1 in 395
Eye (C69)	108	0.3	1.0	0.9	1 in 1,250	1 in 863
Brain (C71)	590	1.4	5.6	4.7	1 in 229	1 in 156
Other central nervous system (C70, C72)	33	0.1	0.3	0.3	1 in 3,733	1 in 3,318
Thyroid (C73)	1,041	2.5	10.2	9.0	1 in 127	1 in 113
Other endocrine organs (C74–C75)	34	0.1	0.3	0.3	1 in 3,539	1 in 2,903
Hodgkin lymphoma (C81)	183	0.4	1.8	1.7	1 in 735	1 in 589
Non-Hodgkin lymphoma (C82–C85, C96)	1,649	3.9	15.1	11.3	1 in 90	1 in 52
<i>All lymphomas (C81–C85, C96)</i>	<i>1,832</i>	<i>4.4</i>	<i>16.9</i>	<i>13.0</i>	<i>1 in 80</i>	<i>1 in 48</i>
Immunoproliferative neoplasms (C88)	34	0.1	0.3	0.2	1 in 6,517	1 in 2,187
Myeloma (C90)	516	1.2	4.6	3.2	1 in 308	1 in 157
Lymphoid leukaemia (C91)	495	1.2	4.5	3.8	1 in 307	1 in 189
Myeloid leukaemia (C92–C94)	538	1.3	4.9	3.9	1 in 283	1 in 171
Leukaemia, unspecified (C95)	31	0.1	0.3	0.2	1 in 6,626	1 in 2,970
<i>All leukaemias (C91–C95)</i>	<i>1,064</i>	<i>2.5</i>	<i>9.8</i>	<i>7.8</i>	<i>1 in 144</i>	<i>1 in 87</i>
Polycythaemia rubra vera (D45)	128	0.3	1.2	0.8	1 in 1,219	1 in 621
Myelodysplastic syndromes (D46)	407	1.0	3.4	2.1	1 in 693	1 in 212
Other chronic myeloproliferative diseases (D47 ^(b))	151	0.4	1.3	0.9	1 in 1,147	1 in 519
Unknown primary site (C26, C39, C76, C80)	1,705	4.1	14.7	9.8	1 in 116	1 in 50
All cancers (C00–C96^(a), D45–D47^(b))	41,776	100.0	386.5	294.8	1 in 4	1 in 3

(a) Excluding non-melanocytic skin cancer (ICD-10 code C44).

(b) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Incidence of lymphoid and haematopoietic neoplasms

Ongoing research into the lymphoid and haematopoietic neoplasms (see Glossary) has revealed that the ICD-10 classification scheme for these neoplasms is no longer satisfactory (WHO 2000, p. 13). For example, lymphomas (ICD-10 codes C81–C85) and lymphoid leukaemias (code C91) were once thought to be quite distinct but are now known to be different patterns of spread of the same cellular dysfunction. The WHO classification scheme (WHO 2001) reflects the current state of knowledge in this field but further research will undoubtedly lead to more changes. Table 2.5 shows the 2003 incidence for these diseases, grouped according to the WHO scheme but with the addition of some new categories to accommodate the vague morphology codes that are sometimes used in source documentation (for example haematology reports). See Appendix A for the list of ICD-O-3 morphology codes that correspond to each group. Note that mortality numbers are not available for these groups because cause of death is coded in the ICD-10 scheme.

Table 2.5: Incidence of malignant lymphoid and haematopoietic neoplasms, Australia, 2003

Group	Males			Females			Persons		
	Cases	ASR (A)	ASR (W)	Cases	ASR (A)	ASR (W)	Cases	ASR (A)	ASR (W)
<i>Lymphoid neoplasms</i>	3,648	38.6	29.5	2,834	26.0	19.8	6,482	31.8	24.4
Hodgkin lymphomas	247	2.5	2.4	183	1.8	1.7	430	2.2	2.1
B-cell neoplasms	2,659	28.2	20.7	2,050	18.6	13.6	4,709	23.0	17.0
T- and NK-cell neoplasms	163	1.7	1.3	116	1.1	0.9	279	1.4	1.1
Non-Hodgkin lymphomas, NOS	427	4.5	3.8	355	3.3	2.8	782	3.9	3.3
Composite Hodgkin/non-Hodgkin lymphoma	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0
Lymphoid neoplasms, NOS	152	1.6	1.2	130	1.1	0.8	282	1.4	1.0
<i>Myeloid neoplasms</i>	1,635	18.2	12.4	1,225	10.8	7.8	2,860	14.0	9.8
Acute myeloid leukaemias	456	4.9	3.7	357	3.3	2.7	813	4.0	3.1
Chronic myeloproliferative diseases	351	3.8	2.7	282	2.5	1.8	633	3.1	2.2
Myelodysplastic syndromes	581	6.8	4.1	407	3.4	2.1	988	4.8	3.0
Myelodysplastic/myeloproliferative diseases	96	1.1	0.7	58	0.5	0.3	154	0.7	0.5
Myeloid neoplasms, NOS	151	1.6	1.3	121	1.1	0.9	272	1.3	1.1
<i>Lymphoid / myeloid neoplasms, NOS</i>	37	0.4	0.3	30	0.3	0.2	67	0.3	0.2
<i>Other lymphoid and haematopoietic neoplasms</i>	57	0.6	0.4	43	0.4	0.3	100	0.5	0.3
Mast cell diseases	3	0.0	0.0	6	0.1	0.1	9	0.0	0.0
Histiocytic and dendritic cell neoplasms	2	0.0	0.0	3	0.0	0.0	5	0.0	0.0
Other immunoproliferative diseases	52	0.6	0.4	34	0.3	0.2	86	0.4	0.3
Total	5,377	57.8	42.6	4,132	37.4	28.0	9,509	46.6	34.8

Source: National Cancer Statistics Clearing House, AIHW.

Cancer incidence in the states and territories, 1999–2003

Cancer registration is based on the patient's state or territory of residence at the time of diagnosis. Differences in age-standardised rates between the states and territories may be explained by variations in underlying cancer risk, the availability and utilisation of diagnostic procedures, reporting and coding inconsistencies, and normal incidence rate fluctuations.

Incidence rates for many types of cancer are considerably lower or higher for the Northern Territory than for other states and territories. These differences are mainly due to low or high incidence of these cancers in Aboriginal and Torres Strait Islander peoples, who comprise 29% of the Northern Territory population (d'Espaignet et al. 1996; Condon et al. 2001), and higher rates of smoking and excessive alcohol consumption in the past (see the final section of this chapter).

Care should be taken when interpreting incidence rates, especially for less common cancers and for states and territories with small populations. To reduce the problems of statistical variation due to a small number of cases, the numbers and rates presented for the states and territories are annual averages over the 5-year period 1999–2003. For annual sex- and cancer-specific data or data cross-classified by other variables (for example age or geographic area), the state and territory cancer registries should be contacted directly.

All cancers, excluding NMSC

For all cancers, excluding NMSC, the highest age-standardised incidence rates occurred in Queensland (492.7 cases per 100,000 persons), followed by Tasmania (471.0), Western Australia (457.2), South Australia (453.1), New South Wales (452.2), the Australian Capital Territory (445.9), Victoria (440.4) and the Northern Territory (413.8).

Melanoma of the skin

The age-standardised rates for all forms of skin cancer are correlated with exposure to ultraviolet radiation (Jelfs et al. 1994). Therefore one would expect to see higher rates in the more northern states and territories, and lower rates in the more southern ones. However, the rates will also be affected by sun-protection behaviour and the percentage of the Indigenous population (which has a lower rate of skin cancer than the non-Indigenous population).

For melanoma of the skin, the highest age-standardised incidence rates occurred in Queensland (65.3 cases per 100,000 persons), followed by Western Australia (54.3), New South Wales (45.4), Tasmania (43.9), the Australian Capital Territory (39.5), South Australia (39.0), Victoria (35.4) and the Northern Territory (33.0).

All cancers, excluding all skin cancers

Given that rates of skin cancer have a geographic component, it is useful to compare the 'all cancers' rates with the effect of skin cancer removed.

For all cancers, excluding all skin cancers, the age-standardised incidence rates become more similar and the ranking of the states and territories changes somewhat. The highest age-standardised incidence rates occurred in Queensland (427.4 cases per 100,000 persons), followed by Tasmania (427.1), South Australia (414.1), New South Wales (406.8), the Australian Capital Territory (406.4), Victoria (405.0), Western Australia (402.9) and the Northern Territory (380.8).

Prostate cancer

For prostate cancer, the highest age-standardised incidence rates occurred in the Australian Capital Territory (143.8 cases per 100,000 males), followed by Tasmania (139.6), South Australia (135.8), Victoria (134.3), New South Wales (132.5), Western Australia (131.1), Queensland (129.5) and the Northern Territory (103.6).

Breast cancer in females

For breast cancer in females, the highest age-standardised incidence rates occurred in the Australian Capital Territory (126.5 cases per 100,000 females), followed by Queensland (117.1), Western Australia (116.5), South Australia (116.4), Victoria (113.7), New South Wales (112.9), Tasmania (111.1) and the Northern Territory (96.8).

Colorectal cancer

For colorectal cancer, the highest age-standardised incidence rates occurred in Tasmania (66.5 cases per 100,000 persons), followed by Queensland (65.7), South Australia (65.7), Victoria (64.8), the Australian Capital Territory (64.3), New South Wales (60.9), Western Australia (60.7) and the Northern Territory (44.3).

Lung cancer

For lung cancer, the highest age-standardised incidence rates occurred in the Northern Territory (52.9 cases per 100,000 persons), followed by Tasmania (49.8), Western Australia (46.2), Queensland (45.1), Victoria (41.9), South Australia (41.6), New South Wales (40.9) and the Australian Capital Territory (30.5).

Table 2.6: Average annual number of new cases of cancer, persons, states and territories, 1999–2003

Cancer site/type (ICD-10 codes)	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Aust
Lip (C00)	247	247	207	94	127	43	4	6	975
Tongue (C01–C02)	164	105	95	39	31	13	5	6	458
Mouth (C03–C06)	150	108	84	42	32	14	7	4	441
Major salivary glands (C07–C08)	85	42	47	22	20	4	4	1	225
Oropharynx (C09–C10)	90	69	58	30	25	7	4	8	291
Nasopharynx (C11)	51	34	13	7	6	2	1	2	115
Hypopharynx (C12–C13)	51	38	33	13	8	3	2	3	151
Pharynx, unspecified (C14)	25	15	19	7	4	3	0	1	75
Nasal cavity, middle ear & sinuses (C30–C31)	47	34	18	12	10	6	2	1	130
Larynx (C32)	200	136	105	52	39	15	5	7	559
<i>Head and neck (C01–C14, C30–C32)</i>	<i>864</i>	<i>582</i>	<i>472</i>	<i>223</i>	<i>174</i>	<i>67</i>	<i>29</i>	<i>34</i>	<i>2,445</i>
Oesophagus (C15)	360	274	201	104	96	40	14	8	1,098
Stomach (C16)	651	539	323	158	175	49	23	6	1,923
Small intestine (C17)	105	66	56	24	28	8	5	1	292
Colon (C18)	2,680	2,068	1,541	669	736	221	103	29	8,046
Rectum (C19–C20)	1,431	1,122	733	379	387	119	54	16	4,242
<i>Colorectal (C18–C20)</i>	<i>4,111</i>	<i>3,190</i>	<i>2,274</i>	<i>1,048</i>	<i>1,123</i>	<i>340</i>	<i>157</i>	<i>45</i>	<i>12,288</i>
Anus (C21)	98	51	47	19	15	8	3	2	241
Liver (C22)	302	239	127	62	56	15	11	8	821
Gallbladder (C23–C24)	201	147	102	53	63	21	6	4	597
Pancreas (C25)	645	492	337	167	165	58	18	10	1,890
Lung, bronchus & trachea (C33–C34)	2,763	2,063	1,559	792	714	256	73	47	8,267
Other thoracic organs (C37–C38)	27	16	16	5	4	2	1	1	73
Bone & articular cartilage (C40–C41)	64	40	37	15	14	3	2	1	176
Melanoma of skin (C43)	3,030	1,725	2,311	983	633	215	111	48	9,054
Mesothelioma (C45)	184	118	101	69	55	11	5	1	544
Kaposi sarcoma (C46)	29	18	5	4	5	0	1	0	63
Peritoneum & retroperitoneum (C48)	53	27	35	9	11	2	2	0	139
Other connective and soft tissue (C47, C49)	155	146	81	35	66	18	5	4	510
Breast (C50)	3,926	2,910	2,143	1,094	995	290	188	60	11,607
Vulva (C51)	76	51	35	21	19	9	2	3	217
Vagina (C52)	27	11	11	7	6	2	1	0	66
Cervix (C53)	256	159	159	79	51	19	10	9	742
Uterus, body (C54)	464	415	297	120	154	33	19	8	1,509
Uterus, unspecified (C55)	32	27	8	3	0	2	2	0	73
Ovary (C56)	375	303	199	107	95	28	17	6	1,130
Other female genital organs (C57)	20	16	9	7	6	2	1	0	60
Placenta (C58)	2	1	1	0	1	0	0	0	5
<i>Gynaecological (C51–C58)</i>	<i>1,251</i>	<i>984</i>	<i>719</i>	<i>343</i>	<i>331</i>	<i>95</i>	<i>52</i>	<i>26</i>	<i>3,802</i>

(continued)

Table 2.6 (continued): Average annual number of new cases of cancer, persons, states and territories, 1999–2003

Cancer site/type (ICD-10 codes)	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Aust
Penis (C60)	25	16	14	6	5	2	2	1	70
Prostate (C61)	4,048	2,930	2,046	1,039	1,035	318	156	44	11,617
Testis (C62)	213	145	107	62	44	18	13	5	607
Other male genital organs (C63)	7	4	3	1	2	1	1	0	20
Kidney (C64)	684	517	358	176	189	62	31	8	2,025
Bladder (C67)	804	380	656	168	185	64	29	5	2,291
Other urinary organs (C65–C66, C68)	147	71	90	35	27	7	3	1	382
Eye (C69)	74	50	53	19	27	5	4	1	233
Brain (C71)	449	360	236	122	109	34	19	7	1,336
Other central nervous system (C70, C72)	28	17	13	4	6	1	2	0	70
Thyroid (C73)	454	225	251	103	85	29	17	7	1,171
Other endocrine organs (C74–C75)	28	18	16	9	4	2	1	0	78
Hodgkin lymphoma (C81)	154	117	67	37	33	10	6	4	428
Non-Hodgkin lymphoma (C82–C85, C96)	1,177	961	584	310	345	95	50	14	3,536
<i>All lymphomas (C81–C85, C96)</i>	<i>1,331</i>	<i>1,078</i>	<i>651</i>	<i>347</i>	<i>379</i>	<i>106</i>	<i>55</i>	<i>18</i>	<i>3,964</i>
Immunoproliferative neoplasms (C88)	27	24	15	10	7	1	1	0	85
Myeloma (C90)	401	285	198	97	104	29	11	2	1,127
Lymphoid leukaemia (C91)	407	246	268	103	133	28	13	3	1,202
Myeloid leukaemia (C92–C94)	441	295	225	96	128	30	18	7	1,238
Leukaemia, unspecified (C95)	40	17	7	7	4	4	0	0	80
<i>All leukaemias (C91–C95)</i>	<i>888</i>	<i>558</i>	<i>500</i>	<i>206</i>	<i>265</i>	<i>62</i>	<i>32</i>	<i>9</i>	<i>2,521</i>
Polycythaemia rubra vera (D45) ^(b)	70	54	62	5	2	1	3	0	197
Myelodysplastic syndromes (D46) ^(b)	232	203	174	72	3	10	6	0	701
Other chronic myeloproliferative diseases (D47) ^{(b)(c)}	76	76	72	32	1	3	2	0	262
Unknown primary site (C26, C39, C76, C80)	1,338	706	527	228	278	87	46	26	3,237
All cancers (C00–C96^(a), D45–D47^(c))	30,389	21,589	17,196	8,042	7,607	2,383	1,147	445	88,799

(a) Excluding non-melanocytic skin cancer (ICD-10 code C44).

(b) Due to ICD-O-3 coding changes these conditions were not recorded as malignant until 2002 to 2004, depending on the state or territory. Therefore the averages given are under-representative of the true averages.

(c) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.7: Average annual age-standardised rates of cancer incidence, persons, states and territories, 1999–2003

Cancer site/type (ICD-10 codes)	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Aust
Lip (C00)	3.7	5.1	5.9	5.2	7.7	8.7	1.5	4.7	5.0
Tongue (C01–C02)	2.5	2.1	2.7	2.2	1.9	2.7	1.9	4.3	2.4
Mouth (C03–C06)	2.2	2.2	2.4	2.3	1.9	2.8	2.5	3.9	2.3
Major salivary glands (C07–C08)	1.3	0.9	1.3	1.2	1.2	0.8	1.3	1.7	1.2
Oropharynx (C09–C10)	1.4	1.4	1.6	1.6	1.5	1.5	1.4	5.7	1.5
Nasopharynx (C11)	0.8	0.7	0.4	0.4	0.4	0.4	0.3	1.7	0.6
Hypopharynx (C12–C13)	0.8	0.8	0.9	0.7	0.5	0.5	0.6	3.0	0.8
Pharynx, unspecified (C14)	0.4	0.3	0.6	0.4	0.3	0.5	0.2	1.5	0.4
Nasal cavity, middle ear & sinuses (C30–C31)	0.7	0.7	0.5	0.7	0.6	1.2	0.8	0.6	0.7
Larynx (C32)	3.0	2.8	3.0	2.9	2.3	3.0	1.9	6.4	2.9
<i>Head and neck (C01–C14, C30–C32)</i>	<i>12.9</i>	<i>11.9</i>	<i>13.4</i>	<i>12.5</i>	<i>10.5</i>	<i>13.3</i>	<i>10.9</i>	<i>28.7</i>	<i>12.6</i>
Oesophagus (C15)	5.3	5.6	5.8	6.0	5.6	7.9	6.1	9.2	5.7
Stomach (C16)	9.6	10.9	9.4	9.2	10.2	9.5	9.7	6.7	9.9
Small intestine (C17)	1.6	1.3	1.6	1.4	1.7	1.5	1.9	0.4	1.5
Colon (C18)	39.7	42.0	44.7	38.9	42.9	43.2	42.4	28.9	41.5
Rectum (C19–C20)	21.2	22.9	21.0	21.8	22.8	23.4	21.9	15.4	21.8
<i>Colorectal (C18–C20)</i>	<i>60.9</i>	<i>64.8</i>	<i>65.7</i>	<i>60.7</i>	<i>65.7</i>	<i>66.5</i>	<i>64.3</i>	<i>44.3</i>	<i>63.3</i>
Anus (C21)	1.5	1.0	1.3	1.1	0.9	1.5	1.0	1.2	1.2
Liver (C22)	4.5	4.9	3.7	3.6	3.3	3.0	4.4	7.5	4.2
Gallbladder (C23–C24)	3.0	3.0	3.0	3.1	3.6	4.1	2.3	4.7	3.1
Pancreas (C25)	9.5	10.0	9.8	9.7	9.6	11.3	7.6	10.2	9.7
Lung, bronchus & trachea (C33–C34)	40.9	41.9	45.1	46.2	41.6	49.8	30.5	52.9	42.6
Other thoracic organs (C37–C38)	0.4	0.3	0.5	0.3	0.3	0.4	0.5	0.5	0.4
Bone & articular cartilage (C40–C41)	1.0	0.8	1.0	0.8	0.9	0.5	0.7	0.8	0.9
Melanoma of skin (C43)	45.4	35.4	65.3	54.3	39.0	43.9	39.5	33.0	46.6
Mesothelioma (C45)	2.7	2.4	2.9	4.0	3.2	2.1	2.1	0.8	2.8
Kaposi sarcoma (C46)	0.4	0.4	0.2	0.2	0.3	0.0	0.4	0.4	0.3
Peritoneum & retroperitoneum (C48)	0.8	0.5	1.0	0.5	0.7	0.3	0.7	0.0	0.7
Other connective and soft tissue (C47, C49)	2.3	3.0	2.3	1.9	4.0	3.7	1.9	2.1	2.6
Kidney (C64)	10.2	10.6	10.2	9.9	11.3	12.3	12.0	6.2	10.4
Bladder (C67)	11.8	7.7	19.1	10.0	10.6	12.5	12.6	7.2	11.8
Other urinary organs (C65–C66, C68)	2.2	1.4	2.6	2.0	1.6	1.4	1.5	1.5	2.0
Eye (C69)	1.1	1.0	1.5	1.1	1.7	1.1	1.5	0.3	1.2
Brain (C71)	6.7	7.4	6.7	6.7	6.7	6.9	6.8	5.3	6.9
Other central nervous system (C70, C72)	0.4	0.3	0.4	0.2	0.4	0.3	0.6	0.6	0.4
Thyroid (C73)	6.9	4.6	7.0	5.5	5.5	5.9	5.3	3.8	6.0
Other endocrine organs (C74–C75)	0.4	0.4	0.4	0.5	0.2	0.3	0.5	0.2	0.4
Hodgkin lymphoma (C81)	2.3	2.4	1.9	1.9	2.2	2.2	1.7	2.9	2.2

(continued)

Table 2.7 (continued): Average annual age-standardised rates of cancer incidence, persons, states and territories, 1999–2003

Cancer site/type (ICD-10 codes)	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Aust
Non-Hodgkin lymphoma (C82–C85, C96)	17.5	19.6	16.7	17.7	20.7	18.9	19.4	10.6	18.2
<i>All lymphomas (C81–C85, C96)</i>	<i>19.9</i>	<i>22.0</i>	<i>18.6</i>	<i>19.6</i>	<i>22.9</i>	<i>21.2</i>	<i>21.1</i>	<i>13.5</i>	<i>20.4</i>
Immunoproliferative neoplasms (C88)	0.4	0.5	0.4	0.6	0.4	0.2	0.5	0.2	0.4
Myeloma (C90)	5.9	5.8	5.7	5.7	6.1	5.6	4.5	3.4	5.8
Lymphoid leukaemia (C91)	6.1	5.0	7.6	5.8	8.0	5.6	5.1	2.3	6.2
Myeloid leukaemia (C92–C94)	6.6	6.0	6.4	5.5	7.6	5.9	7.2	5.5	6.4
Leukaemia, unspecified (C95)	0.6	0.4	0.2	0.4	0.2	0.8	0.1	0.0	0.4
<i>All leukaemias (C91–C95)</i>	<i>13.2</i>	<i>11.4</i>	<i>14.3</i>	<i>11.7</i>	<i>15.9</i>	<i>12.4</i>	<i>12.5</i>	<i>7.8</i>	<i>13.0</i>
Polycythaemia rubra vera (D45) ^(b)	1.0	1.1	1.8	0.3	0.1	0.2	1.3	0.0	1.0
Myelodysplastic syndromes (D46) ^(b)	3.4	4.1	5.1	4.3	0.2	1.9	2.9	0.0	3.6
Other chronic myeloproliferative diseases (D47) ^{(b)(c)}	1.1	1.5	2.1	1.9	0.1	0.6	1.0	0.0	1.4
Unknown primary site (C26, C39, C76, C80)	19.8	14.3	15.4	13.4	16.0	17.0	19.8	32.2	16.7
All cancers (C00–C96^(a), D45–D47^(c))	452.2	440.4	492.7	457.2	453.1	471.0	445.9	413.8	457.4

(a) Excluding non-melanocytic skin cancer (ICD-10 code C44).

(b) Due to ICD-O-3 coding changes these conditions were not recorded as malignant until 2002 to 2004, depending on the state or territory. Therefore the averages given are under-representative of the true averages.

(c) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.8: Average annual number of new cases of cancer, males, states and territories, 1999–2003

Cancer site/type (ICD-10 codes)	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Aust
Lip (C00)	176	174	150	67	95	31	3	5	701
Tongue (C01–C02)	109	69	64	28	20	11	4	5	310
Mouth (C03–C06)	91	64	53	28	20	9	4	3	272
Major salivary glands (C07–C08)	56	23	31	13	11	2	2	1	137
Oropharynx (C09–C10)	69	52	45	25	19	6	3	7	226
Nasopharynx (C11)	34	25	10	6	4	1	0	1	83
Hypopharynx (C12–C13)	42	31	28	12	7	2	2	3	127
Pharynx, unspecified (C14)	20	11	15	6	3	2	0	1	58
Nasal cavity, middle ear & sinuses (C30–C31)	30	22	11	9	7	5	1	1	86
Larynx (C32)	177	118	97	45	33	13	4	6	494
<i>Head and neck (C01–C14, C30–C32)</i>	<i>628</i>	<i>415</i>	<i>354</i>	<i>171</i>	<i>125</i>	<i>50</i>	<i>21</i>	<i>29</i>	<i>1,793</i>
Oesophagus (C15)	230	177	142	71	62	29	9	6	726
Stomach (C16)	414	339	218	105	115	31	14	4	1,240
Small intestine (C17)	60	35	32	15	16	4	2	0	164
Colon (C18)	1,359	1,052	798	354	373	110	53	17	4,116
Rectum (C19–C20)	884	676	460	238	225	71	33	12	2,599
<i>Colorectal (C18–C20)</i>	<i>2,243</i>	<i>1,728</i>	<i>1,258</i>	<i>591</i>	<i>598</i>	<i>181</i>	<i>86</i>	<i>30</i>	<i>6,715</i>
Anus (C21)	46	23	19	8	4	4	1	1	107
Liver (C22)	216	173	89	47	40	11	7	6	589
Gallbladder (C23–C24)	79	62	47	25	26	9	2	2	251
Pancreas (C25)	322	250	179	84	88	28	9	7	967
Lung, bronchus & trachea (C33–C34)	1,810	1,313	1,050	512	464	160	46	34	5,389
Other thoracic organs (C37–C38)	18	10	11	3	2	1	1	0	47
Bone & articular cartilage (C40–C41)	35	22	21	8	9	1	1	1	98
Melanoma of skin (C43)	1,778	926	1,331	580	346	108	60	26	5,155
Mesothelioma (C45)	149	96	84	59	45	9	5	1	449
Kaposi sarcoma (C46)	26	14	5	3	5	0	1	0	53
Peritoneum & retroperitoneum (C48)	13	6	7	2	3	0	0	0	33
Other connective and soft tissue (C47, C49)	84	81	48	22	37	10	3	3	287
Breast (C50)	32	22	15	7	7	1	1	1	87
Penis (C60)	25	16	14	6	5	2	2	1	70
Prostate (C61)	4,048	2,930	2,046	1,039	1,035	318	156	44	11,617
Testis (C62)	213	145	107	62	44	18	13	5	607
Other male genital organs (C63)	7	4	3	1	2	1	1	0	20
Kidney (C64)	430	326	230	112	126	38	18	5	1,286
Bladder (C67)	592	274	500	125	136	48	23	5	1,702
Other urinary organs (C65–C66, C68)	69	43	42	20	14	4	1	1	194
Eye (C69)	44	31	33	13	14	3	2	1	141
Brain (C71)	262	205	133	70	63	20	11	5	769

(continued)

Table 2.8 (continued): Average annual number of new cases of cancer, males, states and territories, 1999–2003

Cancer site/type (ICD-10 codes)	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Aust
Other central nervous system (C70, C72)	12	9	7	2	3	1	0	0	35
Thyroid (C73)	107	58	67	27	22	6	4	3	294
Other endocrine organs (C74–C75)	17	10	8	5	2	1	1	0	44
Hodgkin lymphoma (C81)	81	67	37	21	21	6	3	3	239
Non-Hodgkin lymphoma (C82–C85, C96)	645	511	325	173	188	53	28	9	1,932
<i>All lymphomas (C81–C85, C96)</i>	<i>725</i>	<i>578</i>	<i>362</i>	<i>194</i>	<i>209</i>	<i>59</i>	<i>31</i>	<i>12</i>	<i>2,170</i>
Immunoproliferative neoplasms (C88)	14	15	10	5	4	1	1	0	50
Myeloma (C90)	223	164	111	54	58	15	6	2	632
Lymphoid leukaemia (C91)	242	145	155	65	80	18	9	2	716
Myeloid leukaemia (C92–C94)	255	163	136	53	74	17	11	4	713
Leukaemia, unspecified (C95)	22	10	4	5	2	2	0	0	44
<i>All leukaemias (C91–C95)</i>	<i>519</i>	<i>319</i>	<i>294</i>	<i>122</i>	<i>157</i>	<i>37</i>	<i>20</i>	<i>6</i>	<i>1,474</i>
Polycythaemia rubra vera (D45) ^(b)	42	27	41	3	1	1	2	0	116
Myelodysplastic syndromes (D46) ^(b)	128	122	103	46	3	6	5	0	412
Other chronic myeloproliferative diseases (D47) ^{(b)(c)}	39	37	36	15	1	1	1	0	130
Unknown primary site (C26, C39, C76, C80)	690	351	280	118	131	42	24	16	1,653
All cancers (C00–C96^(a), D45–D47^(c))	16,568	11,528	9,487	4,419	4,120	1,289	596	258	48,265

(a) Excluding non-melanocytic skin cancer (ICD-10 code C44).

(b) Due to ICD-O-3 coding changes these conditions were not recorded as malignant until 2002 to 2004, depending on the state or territory. Therefore the averages given are under-representative of the true averages.

(c) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.9: Average annual age-standardised rates of cancer incidence, males, states and territories, 1999–2003

Cancer site/type (ICD-10 codes)	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Aust
Lip (C00)	5.7	7.7	8.8	7.6	12.5	13.3	2.2	7.2	7.7
Tongue (C01–C02)	3.4	3.0	3.7	3.2	2.6	4.4	3.1	6.1	3.3
Mouth (C03–C06)	2.9	2.8	3.0	3.2	2.7	3.5	3.2	4.6	2.9
Major salivary glands (C07–C08)	1.9	1.0	1.9	1.6	1.4	0.9	1.4	3.5	1.6
Oropharynx (C09–C10)	2.2	2.2	2.6	2.8	2.5	2.5	2.0	8.6	2.4
Nasopharynx (C11)	1.1	1.1	0.6	0.7	0.6	0.4	0.2	3.0	0.9
Hypopharynx (C12–C13)	1.3	1.4	1.7	1.4	0.9	0.8	1.1	5.3	1.4
Pharynx, unspecified (C14)	0.6	0.5	0.8	0.7	0.3	0.7	0.4	1.8	0.6
Nasal cavity, middle ear & sinuses (C30–C31)	1.0	1.0	0.7	1.0	0.9	2.1	1.1	1.1	1.0
Larynx (C32)	5.6	5.2	5.7	5.3	4.2	5.4	3.9	10.0	5.4
<i>Head and neck (C01–C14, C30–C32)</i>	<i>20.0</i>	<i>18.2</i>	<i>20.7</i>	<i>20.0</i>	<i>16.1</i>	<i>20.8</i>	<i>16.4</i>	<i>43.9</i>	<i>19.5</i>
Oesophagus (C15)	7.5	8.1	8.8	9.0	8.2	12.2	9.3	12.5	8.2
Stomach (C16)	13.7	15.4	14.0	13.6	15.2	13.8	13.1	9.0	14.3
Small intestine (C17)	1.9	1.6	1.9	1.8	2.1	1.8	2.1	0.4	1.8
Colon (C18)	44.7	48.1	50.1	45.8	49.2	47.9	48.4	31.4	47.1
Rectum (C19–C20)	28.5	30.3	27.8	29.4	29.3	30.1	28.9	22.4	29.0
<i>Colorectal (C18–C20)</i>	<i>73.1</i>	<i>78.4</i>	<i>77.9</i>	<i>75.2</i>	<i>78.4</i>	<i>77.9</i>	<i>77.3</i>	<i>53.7</i>	<i>76.1</i>
Anus (C21)	1.5	1.0	1.1	0.9	0.6	1.6	0.9	1.3	1.2
Liver (C22)	7.0	7.7	5.4	5.7	5.2	4.8	6.0	11.8	6.6
Gallbladder (C23–C24)	2.6	2.8	3.0	3.1	3.4	4.0	2.1	4.4	2.9
Pancreas (C25)	10.8	11.5	11.2	10.6	11.6	12.2	9.1	11.3	11.1
Lung, bronchus & trachea (C33–C34)	59.3	59.9	65.7	66.0	61.0	69.3	43.4	70.1	61.5
Other thoracic organs (C37–C38)	0.6	0.4	0.7	0.3	0.3	0.3	0.7	0.4	0.5
Bone & articular cartilage (C40–C41)	1.1	1.0	1.2	0.8	1.1	0.5	0.9	0.9	1.0
Melanoma of skin (C43)	57.1	41.0	78.8	67.7	45.6	46.5	45.9	36.0	56.6
Mesothelioma (C45)	4.9	4.4	5.3	7.6	5.9	3.8	4.1	1.2	5.1
Kaposi sarcoma (C46)	0.8	0.6	0.3	0.4	0.6	0.1	0.5	0.9	0.6
Peritoneum & retroperitoneum (C48)	0.4	0.2	0.5	0.3	0.4	0.1	0.2	0.0	0.4
Other connective and soft tissue (C47, C49)	2.7	3.6	2.8	2.5	5.1	4.2	2.0	2.7	3.2
Breast (C50)	1.1	1.0	0.9	1.0	0.9	0.6	0.8	1.0	1.0
Penis (C60)	0.8	0.7	0.9	0.7	0.7	0.8	1.4	2.0	0.8
Prostate (C61)	132.5	134.3	129.5	131.1	135.8	139.6	143.8	103.6	132.9
Testis (C62)	6.5	6.0	5.9	6.4	6.0	8.1	8.0	3.9	6.3
Other male genital organs (C63)	0.2	0.2	0.2	0.2	0.3	0.4	0.7	0.8	0.2
Kidney (C64)	13.7	14.5	13.8	13.5	16.5	15.9	15.1	7.7	14.2
Bladder (C67)	20.1	13.0	32.2	17.3	18.2	21.4	22.2	12.3	20.1
Other urinary organs (C65–C66, C68)	2.3	2.0	2.6	2.7	1.9	1.8	1.3	1.7	2.2
Eye (C69)	1.4	1.4	1.9	1.6	1.9	1.5	1.5	0.6	1.6

(continued)

Table 2.9 (continued): Average annual age-standardised rates of cancer incidence, males, states and territories, 1999–2003

Cancer site/type (ICD-10 codes)	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Aust
Brain (C71)	8.3	9.0	7.7	8.1	8.2	8.3	8.6	5.9	8.3
Other central nervous system (C70, C72)	0.4	0.4	0.4	0.2	0.5	0.5	0.3	0.2	0.4
Thyroid (C73)	3.3	2.5	3.9	2.9	2.9	2.6	2.5	2.8	3.1
Other endocrine organs (C74–C75)	0.5	0.4	0.5	0.5	0.2	0.3	0.6	0.3	0.5
Hodgkin lymphoma (C81)	2.5	2.8	2.1	2.2	2.8	2.8	1.7	3.0	2.5
Non-Hodgkin lymphoma (C82–C85, C96)	20.8	22.8	19.8	21.3	24.8	22.9	24.7	10.4	21.5
<i>All lymphomas (C81–C85, C96)</i>	<i>23.3</i>	<i>25.6</i>	<i>21.9</i>	<i>23.6</i>	<i>27.6</i>	<i>25.7</i>	<i>26.5</i>	<i>13.4</i>	<i>24.0</i>
Immunoproliferative neoplasms (C88)	0.5	0.7	0.6	0.7	0.5	0.3	0.9	0.4	0.6
Myeloma (C90)	7.4	7.6	7.0	7.0	7.7	6.8	5.3	5.1	7.3
Lymphoid leukaemia (C91)	7.8	6.5	9.3	7.8	10.6	7.7	7.5	3.3	8.0
Myeloid leukaemia (C92–C94)	8.3	7.5	8.5	6.7	10.0	7.8	10.9	5.6	8.2
Leukaemia, unspecified (C95)	0.8	0.4	0.2	0.6	0.3	0.7	0.1	0.0	0.5
<i>All leukaemias (C91–C95)</i>	<i>16.9</i>	<i>14.5</i>	<i>18.1</i>	<i>15.1</i>	<i>20.8</i>	<i>16.2</i>	<i>18.5</i>	<i>8.9</i>	<i>16.7</i>
Polycythaemia rubra vera (D45) ^(b)	1.3	1.2	2.5	0.3	0.1	0.3	1.3	0.0	1.3
Myelodysplastic syndromes (D46) ^(b)	4.7	6.1	7.2	6.7	0.3	2.5	5.4	0.0	5.2
Other chronic myeloproliferative diseases (D47) ^{(b)(c)}	1.3	1.8	2.3	2.0	0.1	0.6	1.5	0.0	1.5
Unknown primary site (C26, C39, C76, C80)	23.2	16.5	18.1	15.9	17.6	19.6	24.7	36.2	19.4
All cancers (C00–C96^(a), D45–D47^(c))	540.5	523.0	586.2	550.7	542.2	561.1	527.2	474.7	545.8

(a) Excluding non-melanocytic skin cancer (ICD-10 code C44).

(b) Due to ICD-O-3 coding changes these conditions were not recorded as malignant until 2002 to 2004, depending on the state or territory. Therefore the averages given are under-representative of the true averages.

(c) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.10: Average annual number of new cases of cancer, females, states and territories, 1999–2003

Cancer site/type (ICD-10 codes)	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Aust
Lip (C00)	71	73	57	26	32	12	1	1	274
Tongue (C01–C02)	55	36	31	11	11	3	1	1	148
Mouth (C03–C06)	59	44	32	13	12	5	3	1	169
Major salivary glands (C07–C08)	29	19	16	9	9	2	2	0	87
Oropharynx (C09–C10)	21	17	13	5	6	1	1	1	65
Nasopharynx (C11)	17	9	3	1	1	1	1	0	33
Hypopharynx (C12–C13)	9	7	5	1	1	1	0	0	24
Pharynx, unspecified (C14)	5	4	5	1	2	1	0	0	17
Nasal cavity, middle ear & sinuses (C30–C31)	17	13	6	4	3	1	1	0	44
Larynx (C32)	23	18	8	7	6	2	0	1	65
<i>Head and neck (C01–C14, C30–C32)</i>	<i>236</i>	<i>166</i>	<i>118</i>	<i>52</i>	<i>50</i>	<i>17</i>	<i>9</i>	<i>5</i>	<i>652</i>
Oesophagus (C15)	130	98	59	32	34	12	5	2	372
Stomach (C16)	237	200	104	53	60	18	9	3	684
Small intestine (C17)	44	31	24	9	12	4	2	0	128
Colon (C18)	1,322	1,016	743	315	363	111	50	11	3,931
Rectum (C19–C20)	547	446	273	142	161	48	21	4	1,643
<i>Colorectal (C18–C20)</i>	<i>1,869</i>	<i>1,462</i>	<i>1,016</i>	<i>457</i>	<i>524</i>	<i>160</i>	<i>71</i>	<i>16</i>	<i>5,573</i>
Anus (C21)	52	28	27	11	10	4	1	1	134
Liver (C22)	86	66	39	16	16	4	4	2	233
Gallbladder (C23–C24)	123	85	55	28	37	12	4	2	346
Pancreas (C25)	322	242	158	82	77	30	9	3	924
Lung, bronchus & trachea (C33–C34)	954	751	508	280	250	95	27	13	2,878
Other thoracic organs (C37–C38)	9	6	5	3	2	1	0	0	26
Bone & articular cartilage (C40–C41)	29	18	16	8	5	1	1	1	78
Melanoma of skin (C43)	1,251	799	981	403	286	106	51	22	3,899
Mesothelioma (C45)	35	21	17	10	9	2	0	0	95
Kaposi sarcoma (C46)	3	4	0	1	1	0	0	0	10
Peritoneum & retroperitoneum (C48)	40	21	28	7	8	1	1	0	107
Other connective and soft tissue (C47, C49)	70	65	33	14	29	9	2	1	223
Breast (C50)	3,894	2,889	2,128	1,087	988	289	187	59	11,520
Vulva (C51)	76	51	35	21	19	9	2	3	217
Vagina (C52)	27	11	11	7	6	2	1	0	66
Cervix (C53)	256	159	159	79	51	19	10	9	742
Uterus, body (C54)	464	415	297	120	154	33	19	8	1,509
Uterus, unspecified (C55)	32	27	8	3	0	2	2	0	73
Ovary (C56)	375	303	199	107	95	28	17	6	1,130
Other female genital organs (C57)	20	16	9	7	6	2	1	0	60
Placenta (C58)	2	1	1	0	1	0	0	0	5

(continued)

Table 2.10 (continued): Average annual number of new cases of cancer, females, states and territories, 1999–2003

Cancer site/type (ICD-10 codes)	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Aust
<i>Gynaecological (C51–C58)</i>	1,251	984	719	343	331	95	52	26	3,802
Kidney (C64)	254	191	128	64	63	25	13	2	739
Bladder (C67)	212	106	156	43	49	17	7	1	589
Other urinary organs (C65–C66, C68)	79	27	49	14	13	3	2	1	188
Eye (C69)	30	20	21	6	12	2	2	0	92
Brain (C71)	187	155	103	51	46	14	8	2	567
Other central nervous system (C70, C72)	15	7	6	2	2	0	1	0	35
Thyroid (C73)	347	167	185	75	63	22	13	4	877
Other endocrine organs (C74–C75)	11	8	8	4	2	1	1	0	35
Hodgkin lymphoma (C81)	73	51	30	16	12	4	3	1	189
Non-Hodgkin lymphoma (C82–C85, C96)	532	449	259	137	157	43	21	6	1,604
<i>All lymphomas (C81–C85, C96)</i>	<i>605</i>	<i>500</i>	<i>289</i>	<i>153</i>	<i>169</i>	<i>47</i>	<i>24</i>	<i>7</i>	<i>1,794</i>
Immunoproliferative neoplasms (C88)	13	9	5	4	3	0	0	0	35
Myeloma (C90)	177	122	87	44	46	13	5	1	495
Lymphoid leukaemia (C91)	165	100	113	39	53	10	5	1	486
Myeloid leukaemia (C92–C94)	186	132	89	43	54	12	7	3	525
Leukaemia, unspecified (C95)	18	7	3	2	2	3	0	0	36
<i>All leukaemias (C91–C95)</i>	<i>369</i>	<i>239</i>	<i>206</i>	<i>84</i>	<i>108</i>	<i>25</i>	<i>12</i>	<i>4</i>	<i>1,047</i>
Polycythaemia rubra vera (D45) ^(b)	28	27	21	3	1	0	2	0	81
Myelodysplastic syndromes (D46) ^(b)	104	82	71	26	1	4	2	0	289
Other chronic myeloproliferative diseases (D47) ^{(b)(c)}	37	39	36	17	0	2	1	0	133
Unknown primary site (C26, C39, C76, C80)	648	355	247	110	147	45	22	11	1,584
All cancers (C00–C96^(a), D45–D47^(c))	13,822	10,062	7,709	3,623	3,487	1,093	551	187	40,534

(a) Excluding non-melanocytic skin cancer (ICD-10 code C44).

(b) Due to ICD-O-3 coding changes these conditions were not recorded as malignant until 2002 to 2004, depending on the state or territory. Therefore the averages given are under-representative of the true averages.

(c) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.11: Average annual age-standardised rates of cancer incidence, females, states and territories, 1999–2003

Cancer site/type (ICD-10 codes)	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Aust
Lip (C00)	2.0	2.7	3.1	2.8	3.4	4.4	0.9	2.0	2.6
Tongue (C01–C02)	1.6	1.4	1.7	1.2	1.2	1.1	0.8	1.9	1.4
Mouth (C03–C06)	1.6	1.7	1.7	1.4	1.3	1.9	1.9	3.1	1.6
Major salivary glands (C07–C08)	0.8	0.8	0.9	1.0	1.0	0.8	1.3	0.2	0.8
Oropharynx (C09–C10)	0.6	0.7	0.7	0.5	0.7	0.5	0.8	2.1	0.6
Nasopharynx (C11)	0.5	0.4	0.2	0.1	0.2	0.3	0.4	0.3	0.3
Hypopharynx (C12–C13)	0.3	0.2	0.3	0.1	0.1	0.2	0.1	0.3	0.2
Pharynx, unspecified (C14)	0.1	0.1	0.3	0.1	0.2	0.3	0.0	0.9	0.2
Nasal cavity, middle ear & sinuses (C30–C31)	0.5	0.5	0.3	0.4	0.3	0.4	0.4	0.0	0.4
Larynx (C32)	0.6	0.7	0.4	0.8	0.7	0.9	0.3	2.0	0.6
<i>Head and neck (C01–C14, C30–C32)</i>	<i>6.6</i>	<i>6.4</i>	<i>6.4</i>	<i>5.6</i>	<i>5.5</i>	<i>6.4</i>	<i>6.1</i>	<i>10.7</i>	<i>6.3</i>
Oesophagus (C15)	3.4	3.4	3.1	3.4	3.5	3.9	3.9	6.1	3.4
Stomach (C16)	6.3	7.3	5.6	5.6	6.2	6.2	7.1	4.7	6.4
Small intestine (C17)	1.2	1.2	1.3	1.0	1.4	1.4	1.7	0.4	1.2
Colon (C18)	35.6	37.1	40.1	33.6	37.8	39.5	37.3	26.1	36.9
Rectum (C19–C20)	15.1	16.6	14.9	15.2	17.4	17.4	15.6	7.2	15.7
<i>Colorectal (C18–C20)</i>	<i>50.7</i>	<i>53.7</i>	<i>54.9</i>	<i>48.7</i>	<i>55.2</i>	<i>56.9</i>	<i>52.9</i>	<i>33.3</i>	<i>52.6</i>
Anus (C21)	1.4	1.0	1.5	1.2	1.2	1.5	1.0	1.0	1.3
Liver (C22)	2.3	2.4	2.1	1.7	1.7	1.4	3.1	3.1	2.2
Gallbladder (C23–C24)	3.3	3.1	2.9	3.0	3.7	4.2	2.6	4.9	3.2
Pancreas (C25)	8.5	8.6	8.4	8.7	7.8	10.4	6.6	8.4	8.5
Lung, bronchus & trachea (C33–C34)	26.3	28.0	27.9	30.3	26.8	34.9	20.6	33.2	27.6
Other thoracic organs (C37–C38)	0.3	0.2	0.3	0.3	0.2	0.4	0.3	0.5	0.3
Bone & articular cartilage (C40–C41)	0.9	0.7	0.9	0.8	0.6	0.6	0.5	0.5	0.8
Melanoma of skin (C43)	36.1	31.2	53.8	42.8	34.1	42.3	33.9	29.1	38.6
Mesothelioma (C45)	0.9	0.8	0.9	1.1	1.0	0.6	0.1	0.3	0.9
Kaposi sarcoma (C46)	0.1	0.1	0.0	0.1	0.1	0.0	0.2	0.0	0.1
Peritoneum & retroperitoneum (C48)	1.1	0.8	1.5	0.8	0.9	0.5	1.1	0.0	1.0
Other connective and soft tissue (C47, C49)	2.0	2.5	1.8	1.4	3.3	3.3	1.7	1.4	2.2
Breast (C50)	112.9	113.7	117.1	116.5	116.4	111.1	126.5	96.8	114.5
Vulva (C51)	2.0	1.9	1.9	2.2	1.9	3.1	1.6	5.2	2.0
Vagina (C52)	0.7	0.4	0.6	0.8	0.6	0.7	0.8	0.0	0.6
Cervix (C53)	7.5	6.3	8.7	8.3	6.3	7.6	6.4	12.5	7.4
Uterus, body (C54)	13.2	16.2	16.3	12.9	17.4	12.2	13.9	16.3	14.8
Uterus, unspecified (C55)	0.9	1.0	0.4	0.3	0.0	0.9	1.2	0.0	0.7
Ovary (C56)	10.6	11.6	10.9	11.5	10.6	10.6	12.4	9.5	11.0
Other female genital organs (C57)	0.6	0.6	0.5	0.7	0.7	0.8	0.5	0.2	0.6

(continued)

Table 2.11 (continued): Average annual age-standardised rates of cancer incidence, females, states and territories, 1999–2003

Cancer site/type (ICD-10 codes)	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Aust
Placenta (C58)	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.1
<i>Gynaecological (C51–C58)</i>	<i>35.6</i>	<i>38.0</i>	<i>39.4</i>	<i>36.7</i>	<i>37.7</i>	<i>35.9</i>	<i>37.0</i>	<i>43.7</i>	<i>37.3</i>
Kidney (C64)	7.1	7.3	7.0	6.8	7.0	9.3	9.5	4.1	7.2
Bladder (C67)	5.5	3.8	8.4	4.5	4.9	5.7	5.1	1.7	5.4
Other urinary organs (C65–C66, C68)	2.1	1.0	2.7	1.6	1.3	1.1	1.6	1.6	1.8
Eye (C69)	0.8	0.8	1.1	0.6	1.4	0.7	1.4	0.0	0.9
Brain (C71)	5.4	6.0	5.7	5.5	5.4	5.5	5.4	4.8	5.6
Other central nervous system (C70, C72)	0.5	0.3	0.3	0.2	0.3	0.2	0.9	0.9	0.3
Thyroid (C73)	10.4	6.7	10.2	8.0	8.0	9.0	8.0	5.0	8.9
Other endocrine organs (C74–C75)	0.3	0.3	0.4	0.5	0.2	0.4	0.4	0.0	0.4
Hodgkin lymphoma (C81)	2.2	2.0	1.6	1.6	1.6	1.6	1.6	2.6	1.9
Non-Hodgkin lymphoma (C82–C85, C96)	14.7	16.8	14.1	14.8	17.3	15.6	15.3	10.1	15.4
<i>All lymphomas (C81–C85, C96)</i>	<i>16.9</i>	<i>18.9</i>	<i>15.7</i>	<i>16.4</i>	<i>18.9</i>	<i>17.3</i>	<i>16.8</i>	<i>12.6</i>	<i>17.3</i>
Immunoproliferative neoplasms (C88)	0.3	0.3	0.3	0.5	0.3	0.2	0.2	0.0	0.3
Myeloma (C90)	4.8	4.4	4.7	4.6	4.8	4.6	4.0	2.1	4.6
Lymphoid leukaemia (C91)	4.6	3.8	6.1	4.1	5.8	3.8	3.4	1.3	4.7
Myeloid leukaemia (C92–C94)	5.1	4.9	4.8	4.5	5.9	4.5	4.9	5.3	5.0
Leukaemia, unspecified (C95)	0.5	0.3	0.2	0.3	0.2	0.9	0.1	0.0	0.3
<i>All leukaemias (C91–C95)</i>	<i>10.1</i>	<i>9.0</i>	<i>11.1</i>	<i>8.9</i>	<i>11.9</i>	<i>9.2</i>	<i>8.4</i>	<i>6.5</i>	<i>10.0</i>
Polycythaemia rubra vera (D45) ^(b)	0.8	1.0	1.1	0.3	0.1	0.1	1.2	0.0	0.8
Myelodysplastic syndromes (D46) ^(b)	2.6	2.8	3.7	2.6	0.1	1.3	1.4	0.0	2.6
Other chronic myeloproliferative diseases (D47) ^{(b)(c)}	1.0	1.4	2.0	1.8	0.0	0.6	0.7	0.0	1.2
Unknown primary site (C26, C39, C76, C80)	17.0	12.5	13.0	11.4	14.7	15.6	16.4	28.4	14.4
All cancers (C00–C96^(a), D45–D47^(c))	387.6	382.4	420.3	386.8	389.9	407.1	389.2	348.0	392.6

(a) Excluding non-melanocytic skin cancer (ICD-10 code C44).

(b) Due to ICD-O-3 coding changes these conditions were not recorded as malignant until 2002 to 2004, depending on the state or territory. Therefore the averages given are under-representative of the true averages.

(c) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Incidence trends 1983–2003

Numbers

The numbers of new cases over the period 1983–2003 are shown in tables 2.12–2.14. Note that cancers for which the numbers are small are subject to large percentage fluctuations from one year to the next. Therefore the following comments are restricted to National Health Priority Area (NHPA) cancers and cancers for which the number of cases in 1993 was at least 500 persons.

- The total number of cancers diagnosed in 2003 was 26% higher than in 1993 (24% for males and 29% for females), compared with 12% population growth over this period.
- Among the NHPA cancers, cases of cervical cancer were 29% lower in 2003 than in 1993, and there were increases for melanoma (up 41%: 49% in males, 31% in females), non-Hodgkin lymphoma (up 36%: 34% in males, 39% in females), breast cancer in females (up 34%), colorectal cancer (up 27%: 29% in males, 26% in females), prostate cancer (up 21%) and lung cancer (up 13%: 3.1% in males, 34% in females).
- Among other cancers, there were major increases between 1993 and 2003 for thyroid cancer (up 106%: 139% in males (but small numbers), 97% in females), myeloma (up 44%: 36% in males, 54% in females), kidney cancer (up 39%: 45% in males, 29% in females), uterine cancer (up 31%), pancreatic cancer (up 30%: 35% in males, 25% in females), oesophageal cancer (up 26%: 35% in males, 11% in females), leukaemia (up 23%: 24% in males, 21% in females), brain cancer (up 22%: 28% in males, 15% in females) and cancers of unknown primary site (up 18%: 15% in males, 21% in females).

Age-standardised rates

Age-standardised incidence rates (against the Australian 2001 Standard Population) over the period 1983–2003 are shown in tables 2.15–2.17. Note that cancers for which the rates are small are subject to large percentage fluctuations from one year to the next. Therefore the following comments are restricted to NHPA cancers and cancers for which the 1993 rate was at least 5.0 per 100,000.

- The rate for all cancers (excluding NMSC) was 0.7% lower in 2003 than in 1993.
- Among the NHPA cancers the largest decrease in rate from 1993 to 2003 was for cervical cancer (down 41%), followed by prostate cancer (12%), lung cancer (11%: down 20% in males, up 6.1% in females) and colorectal cancer (1.5%: 1.7% in males, 2.0% in females).
- The largest increase in rate for NHPA cancers from 1993 to 2003 was for melanoma (up 14%: 19% in males, 6.8% in females), followed by non-Hodgkin lymphoma (7.2%: 4.4% in males, 9.9% in females) and breast cancer in females (6.1%).
- In other cancers in persons, the rate decreased by at least 10% for bladder cancer (down 23%: 25% in males, 19% in females), stomach cancer (down 22%: 26% in males, 17% in females) and cancers of unknown primary site (down 10%: 13% in males, 7.9% in females).
- In other cancers in males, the rate decreased by at least 10% for lip cancer (down 27%) and laryngeal cancer (27%). The rate increased by over 10% for liver cancer (up 29%), testicular cancer (25%) and kidney cancer (11%).
- In other cancers in females, the rate decreased by at least 10% only for ovarian cancer (down 19%). The rate increased by at least 10% only for thyroid cancer (up 67%).

Table 2.12: New cases of cancer, persons, Australia, selected years, 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
NHPA cancers						
Colorectal (C18–C20)	7,118	8,249	9,836	11,115	12,536	27.5
Lung, bronchus & trachea (C33–C34)	6,117	6,695	7,327	8,010	8,249	12.6
Melanoma of skin (C43)	3,803	6,044	6,765	7,974	9,524	40.8
Non-Hodgkin lymphoma (C82–C85, C96)	1,614	2,080	2,723	3,190	3,699	35.8
Other cancers						
Lip (C00)	663	846	986	1,135	987	0.1
Tongue (C01–C02)	286	328	368	429	492	33.7
Mouth (C03–C06)	350	363	415	480	466	12.3
Major salivary glands (C07–C08)	126	150	182	216	229	25.8
Oropharynx (C09–C10)	201	197	207	272	292	41.1
Nasopharynx (C11)	84	86	125	105	107	–14.4
Hypopharynx (C12–C13)	146	172	181	158	133	–26.5
Pharynx, unspecified (C14)	34	52	66	63	70	6.1
Nasal cavity, middle ear & sinuses (C30–C31)	83	98	140	125	130	–7.1
Larynx (C32)	600	580	592	621	557	–5.9
<i>Head and neck (C01–C14, C30–C32)</i>	<i>1,910</i>	<i>2,026</i>	<i>2,276</i>	<i>2,469</i>	<i>2,476</i>	<i>8.8</i>
Oesophagus (C15)	610	842	919	1,001	1,154	25.6
Stomach (C16)	1,910	1,779	1,845	1,902	1,873	1.5
Small intestine (C17)	94	134	155	259	347	123.9
Colon (C18)	4,694	5,472	6,479	7,281	8,144	25.7
Rectum (C19–C20)	2,424	2,777	3,357	3,834	4,392	30.8
Anus (C21)	98	151	161	218	252	56.5
Liver (C22)	205	300	498	627	890	78.7
Gallbladder (C23–C24)	434	502	498	616	586	17.7
Pancreas (C25)	1,176	1,345	1,530	1,793	1,996	30.5
Other thoracic organs (C37–C38)	40	61	71	87	74	4.2
Bone & articular cartilage (C40–C41)	150	148	153	158	167	9.2
Mesothelioma (C45)	144	275	370	472	633	71.1
Kaposi sarcoma (C46)	18	146	207	94	57	–72.5
Peritoneum & retroperitoneum (C48)	36	46	75	111	165	120.0
Other connective and soft tissue (C47, C49)	337	368	419	543	491	17.2
Breast (C50)	5,421	6,784	8,854	10,815	11,889	34.3
Vulva (C51)	132	150	177	213	220	24.3
Vagina (C52)	50	45	64	57	67	4.7
Cervix (C53)	995	1,062	1,017	863	725	–28.7
Uterus, body (C54)	876	1,029	1,227	1,368	1,613	31.5
Uterus, unspecified (C55)	53	39	15	35	85	466.7

(continued)

Table 2.12 (continued): New cases of cancer, persons, Australia, selected years, 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
Ovary (C56)	856	893	1,076	1,120	1,084	0.7
Other female genital organs (C57)	22	26	39	43	57	46.2
Placenta (C58)	9	10	5	8	6	20.0
<i>Gynaecological (C51–C58)</i>	<i>2,993</i>	<i>3,254</i>	<i>3,620</i>	<i>3,707</i>	<i>3,857</i>	<i>6.5</i>
Penis (C60)	46	34	54	67	67	24.1
Prostate (C61)	3,747	4,775	11,154	10,073	13,526	21.3
Testis (C62)	316	355	474	564	638	34.6
Other male genital organs (C63)	5	8	25	23	24	–4.0
Kidney (C64)	799	1,071	1,454	1,830	2,019	38.9
Bladder (C67)	2,103	2,209	2,240	2,199	2,229	–0.5
Other urinary organs (C65–C66, C68)	327	310	327	357	362	10.7
Eye (C69)	160	165	232	257	254	9.5
Brain (C71)	883	1,006	1,114	1,193	1,360	22.1
Other central nervous system (C70, C72)	49	71	61	65	71	16.4
Thyroid (C73)	421	471	680	981	1,402	106.2
Other endocrine organs (C74–C75)	45	79	82	81	76	–7.3
Hodgkin lymphoma (C81)	334	349	351	399	430	22.5
<i>All lymphomas (C81–C85, C96)</i>	<i>1,948</i>	<i>2,429</i>	<i>3,074</i>	<i>3,589</i>	<i>4,129</i>	<i>34.3</i>
Immunoproliferative neoplasms (C88)	15	22	45	82	86	91.1
Myeloma (C90)	558	668	801	1,065	1,153	43.9
Lymphoid leukaemia (C91)	688	871	986	1,119	1,214	23.1
Myeloid leukaemia (C92–C94)	714	874	990	1,110	1,238	25.1
Leukaemia, unspecified (C95)	93	96	81	82	72	–11.1
<i>All leukaemias (C91–C95)</i>	<i>1,495</i>	<i>1,841</i>	<i>2,057</i>	<i>2,311</i>	<i>2,524</i>	<i>22.7</i>
Polycythaemia rubra vera (D45)	27	39	105	145	326	210.5
Myelodysplastic syndromes (D46)	6	28	161	396	988	513.7
Other chronic myeloproliferative diseases (D47 ^(b))	35	64	129	263	303	134.9
Unknown primary site (C26, C39, C76, C80)	2,280	2,670	2,925	3,124	3,454	18.1
All cancers (C00–C96^(a), D45–D47^(b))	48,542	58,310	73,759	81,771	93,194	26.3

(a) Excludes non-melanocytic skin cancer (ICD-10 code C44).

(b) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.13: New cases of cancer, males, Australia, selected years, 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
NHPA cancers						
Colorectal (C18–C20)	3,702	4,415	5,314	6,031	6,857	29.0
Lung, bronchus & trachea (C33–C34)	4,788	4,949	5,120	5,448	5,281	3.1
Melanoma of skin (C43)	1,813	3,213	3,715	4,458	5,535	49.0
Prostate (C61)	3,747	4,775	11,154	10,073	13,526	21.3
Non-Hodgkin lymphoma (C82–C85, C96)	845	1,143	1,533	1,711	2,050	33.7
Other cancers						
Lip (C00)	558	664	758	837	717	–5.4
Tongue (C01–C02)	197	227	265	279	343	29.4
Mouth (C03–C06)	229	239	273	285	287	5.1
Major salivary glands (C07–C08)	71	90	111	121	136	22.5
Oropharynx (C09–C10)	160	156	155	215	232	49.7
Nasopharynx (C11)	59	67	91	80	77	–15.4
Hypopharynx (C12–C13)	124	139	155	136	119	–23.2
Pharynx, unspecified (C14)	23	42	50	49	55	10.0
Nasal cavity, middle ear & sinuses (C30–C31)	51	69	101	80	82	–18.8
Larynx (C32)	534	516	538	563	498	–7.4
<i>Head and neck (C01–C14, C30–C32)</i>	<i>1,448</i>	<i>1,545</i>	<i>1,739</i>	<i>1,808</i>	<i>1,829</i>	<i>5.2</i>
Oesophagus (C15)	373	499	567	627	765	34.9
Stomach (C16)	1,206	1,154	1,219	1,233	1,216	–0.2
Small intestine (C17)	44	76	94	133	195	107.4
Colon (C18)	2,286	2,745	3,280	3,671	4,185	27.6
Rectum (C19–C20)	1,416	1,670	2,034	2,360	2,672	31.4
Anus (C21)	35	67	77	92	105	36.4
Liver (C22)	157	226	368	467	614	66.8
Gallbladder (C23–C24)	175	196	192	251	238	24.0
Pancreas (C25)	630	688	773	885	1,047	35.4
Other thoracic organs (C37–C38)	33	37	48	50	48	0.0
Bone & articular cartilage (C40–C41)	88	94	90	86	99	10.0
Mesothelioma (C45)	130	244	318	412	524	64.8
Kaposi sarcoma (C46)	12	139	192	78	50	–74.0
Peritoneum & retroperitoneum (C48)	15	22	28	30	41	46.4
Other connective and soft tissue (C47, C49)	190	211	231	312	296	28.1
Breast (C50)	45	59	64	91	101	57.8
Penis (C60)	46	34	54	67	67	24.1
Testis (C62)	316	355	474	564	638	34.6
Other male genital organs (C63)	5	8	25	23	24	–4.0
Kidney (C64)	517	656	898	1,163	1,302	45.0

(continued)

Table 2.13 (continued): New cases of cancer, males, Australia, selected years, 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
Bladder (C67)	1,571	1,612	1,682	1,611	1,649	–2.0
Other urinary organs (C65–C66, C68)	168	149	162	179	171	5.6
Eye (C69)	85	88	143	151	146	2.1
Brain (C71)	492	561	602	684	770	27.9
Other central nervous system (C70, C72)	28	37	33	29	38	15.2
Thyroid (C73)	103	124	151	264	361	139.1
Other endocrine organs (C74–C75)	23	44	46	40	42	–8.7
Hodgkin lymphoma (C81)	206	208	193	218	247	28.0
<i>All lymphomas (C81–C85, C96)</i>	<i>1,051</i>	<i>1,351</i>	<i>1,726</i>	<i>1,929</i>	<i>2,297</i>	<i>33.1</i>
Immunoproliferative neoplasms (C88)	8	15	26	57	52	100.0
Myeloma (C90)	288	366	467	597	637	36.4
Lymphoid leukaemia (C91)	421	550	589	653	719	22.1
Myeloid leukaemia (C92–C94)	380	491	552	629	700	26.8
Leukaemia, unspecified (C95)	53	51	40	44	41	2.5
<i>All leukaemias (C91–C95)</i>	<i>854</i>	<i>1,092</i>	<i>1,181</i>	<i>1,326</i>	<i>1,460</i>	<i>23.6</i>
Polycythaemia rubra vera (D45)	17	18	58	89	198	241.4
Myelodysplastic syndromes (D46)	4	15	96	234	581	505.2
Other chronic myeloproliferative diseases (D47 ^(b))	16	35	59	144	152	157.6
Unknown primary site (C26, C39, C76, C80)	1,132	1,395	1,516	1,576	1,749	15.4
All cancers (C00–C96^(a), D45–D47^(b))	25,913	31,228	41,460	44,129	51,418	24.0

(a) Excludes non-melanocytic skin cancer (ICD-10 code C44).

(b) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.14: New cases of cancer, females, Australia, selected years, 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
NHPA cancers						
Colorectal (C18–C20)	3,416	3,834	4,522	5,084	5,679	25.6
Lung, bronchus & trachea (C33–C34)	1,329	1,746	2,207	2,562	2,968	34.5
Melanoma of skin (C43)	1,990	2,831	3,050	3,516	3,989	30.8
Breast (C50)	5,376	6,725	8,790	10,724	11,788	34.1
Cervix (C53)	995	1,062	1,017	863	725	–28.7
Non-Hodgkin lymphoma (C82–C85, C96)	769	937	1,190	1,479	1,649	38.6
Other cancers						
Lip (C00)	105	182	228	298	270	18.4
Tongue (C01–C02)	89	101	103	150	149	44.7
Mouth (C03–C06)	121	124	142	195	179	26.1
Major salivary glands (C07–C08)	55	60	71	95	93	31.0
Oropharynx (C09–C10)	41	41	52	57	60	15.4
Nasopharynx (C11)	25	19	34	25	30	–11.8
Hypopharynx (C12–C13)	22	33	26	22	14	–46.2
Pharynx, unspecified (C14)	11	10	16	14	15	–6.3
Nasal cavity, middle ear & sinuses (C30–C31)	32	29	39	45	48	23.1
Larynx (C32)	66	64	54	58	59	9.3
<i>Head and neck (C01–C14, C30–C32)</i>	<i>462</i>	<i>481</i>	<i>537</i>	<i>661</i>	<i>647</i>	<i>20.5</i>
Oesophagus (C15)	237	343	352	374	389	10.5
Stomach (C16)	704	625	626	669	657	5.0
Small intestine (C17)	50	58	61	126	152	149.2
Colon (C18)	2,408	2,727	3,199	3,610	3,959	23.8
Rectum (C19–C20)	1,008	1,107	1,323	1,474	1,720	30.0
Anus (C21)	63	84	84	126	147	75.0
Liver (C22)	48	74	130	160	276	112.3
Gallbladder (C23–C24)	259	306	306	365	348	13.7
Pancreas (C25)	546	657	757	908	949	25.4
Other thoracic organs (C37–C38)	7	24	23	37	26	13.0
Bone & articular cartilage (C40–C41)	62	54	63	72	68	7.9
Mesothelioma (C45)	14	31	52	60	109	109.6
Kaposi sarcoma (C46)	6	7	15	16	7	–53.3
Peritoneum & retroperitoneum (C48)	21	24	47	81	124	163.8
Other connective and soft tissue (C47, C49)	147	157	188	231	195	3.7
Vulva (C51)	132	150	177	213	220	24.3
Vagina (C52)	50	45	64	57	67	4.7
Uterus, body (C54)	876	1,029	1,227	1,368	1,613	31.5
Uterus, unspecified (C55)	53	39	15	35	85	466.7

(continued)

Table 2.14 (continued): New cases of cancer, females, Australia, selected years, 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
Ovary (C56)	856	893	1,076	1,120	1,084	0.7
Other female genital organs (C57)	22	26	39	43	57	46.2
Placenta (C58)	9	10	5	8	6	20.0
<i>Gynaecological (C51–C58)</i>	<i>2,993</i>	<i>3,254</i>	<i>3,620</i>	<i>3,707</i>	<i>3,857</i>	<i>6.5</i>
Kidney (C64)	282	415	556	667	717	29.0
Bladder (C67)	532	597	558	588	580	3.9
Other urinary organs (C65–C66, C68)	159	161	165	178	191	15.8
Eye (C69)	75	77	89	106	108	21.3
Brain (C71)	391	445	512	509	590	15.2
Other central nervous system (C70, C72)	21	34	28	36	33	17.9
Thyroid (C73)	318	347	529	717	1,041	96.8
Other endocrine organs (C74–C75)	22	35	36	41	34	–5.6
Hodgkin lymphoma (C81)	128	141	158	181	183	15.8
<i>All lymphomas (C81–C85, C96)</i>	<i>897</i>	<i>1,078</i>	<i>1,348</i>	<i>1,660</i>	<i>1,832</i>	<i>35.9</i>
Immunoproliferative neoplasms (C88)	7	7	19	25	34	78.9
Myeloma (C90)	270	302	334	468	516	54.5
Lymphoid leukaemia (C91)	267	321	397	466	495	24.7
Myeloid leukaemia (C92–C94)	334	383	438	481	538	22.8
Leukaemia, unspecified (C95)	40	45	41	38	31	–24.4
<i>All leukaemias (C91–C95)</i>	<i>641</i>	<i>749</i>	<i>876</i>	<i>985</i>	<i>1,064</i>	<i>21.5</i>
Polycythaemia rubra vera (D45)	10	21	47	56	128	172.3
Myelodysplastic syndromes (D46)	2	13	65	162	407	526.2
Other chronic myeloproliferative diseases (D47 ^(b))	19	29	70	119	151	115.7
Unknown primary site (C26, C39, C76, C80)	1,148	1,275	1,409	1,548	1,705	21.0
All cancers (C00–C96^(a), D45–D47^(b))	22,629	27,082	32,299	37,642	41,776	29.3

(a) Excludes non-melanocytic skin cancer (ICD-10 code C44).

(b) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.15: Age-standardised rate of cancer incidence, persons, Australia, selected years, 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
NHPA cancers						
Colorectal (C18–C20)	57.9	58.7	62.3	62.0	61.3	–1.5
Lung, bronchus & trachea (C33–C34)	47.3	46.2	45.6	44.4	40.4	–11.5
Melanoma of skin (C43)	28.0	40.4	41.2	43.9	46.9	13.9
Non-Hodgkin lymphoma (C82–C85, C96)	12.6	14.2	16.9	17.7	18.1	7.2
Other cancers						
Lip (C00)	5.0	5.9	6.1	6.3	4.9	–20.4
Tongue (C01–C02)	2.2	2.2	2.3	2.4	2.4	5.2
Mouth (C03–C06)	2.7	2.5	2.6	2.7	2.3	–12.2
Major salivary glands (C07–C08)	1.0	1.0	1.1	1.2	1.1	–0.3
Oropharynx (C09–C10)	1.5	1.4	1.3	1.5	1.4	11.0
Nasopharynx (C11)	0.6	0.6	0.8	0.6	0.5	–31.9
Hypopharynx (C12–C13)	1.1	1.2	1.1	0.9	0.7	–42.2
Pharynx, unspecified (C14)	0.3	0.4	0.4	0.3	0.3	–15.4
Nasal cavity, middle ear & sinuses (C30–C31)	0.7	0.7	0.9	0.7	0.6	–26.6
Larynx (C32)	4.5	3.9	3.6	3.4	2.7	–24.8
<i>Head and neck (C01–C14, C30–C32)</i>	<i>14.6</i>	<i>13.9</i>	<i>14.1</i>	<i>13.7</i>	<i>12.1</i>	<i>–14.0</i>
Oesophagus (C15)	5.0	6.0	5.8	5.6	5.6	–3.2
Stomach (C16)	15.8	12.9	11.8	10.6	9.2	–22.1
Small intestine (C17)	0.7	0.9	1.0	1.4	1.7	77.9
Colon (C18)	38.4	39.1	41.2	40.7	39.8	–3.2
Rectum (C19–C20)	19.5	19.6	21.1	21.3	21.5	2.0
Anus (C21)	0.8	1.1	1.0	1.2	1.2	22.3
Liver (C22)	1.6	2.1	3.1	3.5	4.4	42.1
Gallbladder (C23–C24)	3.6	3.6	3.2	3.5	2.9	–10.4
Pancreas (C25)	9.6	9.7	9.7	10.1	9.7	0.3
Other thoracic organs (C37–C38)	0.3	0.4	0.4	0.5	0.4	–14.8
Bone & articular cartilage (C40–C41)	1.0	0.9	0.9	0.9	0.8	–5.3
Mesothelioma (C45)	1.1	1.9	2.3	2.6	3.1	34.0
Kaposi sarcoma (C46)	0.2	0.9	1.2	0.5	0.3	–75.6
Peritoneum & retroperitoneum (C48)	0.3	0.3	0.5	0.6	0.8	75.8
Other connective and soft tissue (C47, C49)	2.5	2.5	2.6	3.0	2.4	–5.0
Kidney (C64)	6.2	7.4	9.1	10.1	9.9	9.2
Bladder (C67)	17.1	15.7	14.2	12.3	10.9	–23.2
Other urinary organs (C65–C66, C68)	2.6	2.2	2.0	2.0	1.8	–12.8
Eye (C69)	1.2	1.1	1.4	1.4	1.3	–11.3
Brain (C71)	6.4	6.6	6.7	6.6	6.7	0.6
Other central nervous system (C70, C72)	0.3	0.4	0.4	0.4	0.4	–0.9

(continued)

Table 2.15 (continued): Age-standardised rate of cancer incidence, persons, Australia, selected years, 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
Thyroid (C73)	3.1	3.0	4.0	5.3	7.0	73.3
Other endocrine organs (C74–C75)	0.3	0.5	0.5	0.4	0.4	–17.9
Hodgkin lymphoma (C81)	2.2	2.1	2.0	2.1	2.2	8.6
<i>All lymphomas (C81–C85, C96)</i>	<i>14.8</i>	<i>16.4</i>	<i>18.9</i>	<i>19.8</i>	<i>20.3</i>	<i>7.4</i>
Immunoproliferative neoplasms (C88)	0.1	0.2	0.3	0.5	0.4	51.7
Myeloma (C90)	4.5	4.8	5.1	6.0	5.6	10.7
Lymphoid leukaemia (C91)	5.2	5.9	6.1	6.2	6.0	–1.1
Myeloid leukaemia (C92–C94)	5.5	6.1	6.2	6.2	6.1	–2.3
Leukaemia, unspecified (C95)	0.8	0.7	0.5	0.5	0.4	–34.1
<i>All leukaemias (C91–C95)</i>	<i>11.5</i>	<i>12.7</i>	<i>12.8</i>	<i>12.8</i>	<i>12.4</i>	<i>–3.0</i>
Polycythaemia rubra vera (D45)	0.2	0.3	0.6	0.8	1.6	147.2
Myelodysplastic syndromes (D46)	0.0	0.2	1.1	2.2	4.8	346.6
Other chronic myeloproliferative diseases (D47 ^(b))	0.3	0.5	0.8	1.5	1.5	80.2
Unknown primary site (C26, C39, C76, C80)	18.9	19.4	18.8	17.6	16.8	–10.4
All cancers (C00–C96^(a), D45–D47^(b))	383.6	406.8	459.9	454.3	456.8	–0.7

(a) Excludes non-melanocytic skin cancer (ICD-10 code C44).

(b) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.16: Age-standardised rate of cancer incidence, males, Australia, selected years, 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
NHPA cancers						
Colorectal (C18–C20)	67.9	70.8	74.5	74.5	73.2	–1.7
Lung, bronchus & trachea (C33–C34)	84.5	77.7	71.4	67.5	57.1	–20.1
Melanoma of skin (C43)	28.6	46.0	48.8	52.4	57.9	18.7
Prostate (C61)	80.9	85.7	164.7	127.9	144.2	–12.5
Non-Hodgkin lymphoma (C82–C85, C96)	14.2	17.2	20.7	20.6	21.6	4.4
Other cancers						
Lip (C00)	9.1	10.0	10.2	10.0	7.4	–27.5
Tongue (C01–C02)	3.4	3.2	3.5	3.2	3.5	1.1
Mouth (C03–C06)	3.7	3.5	3.5	3.4	3.0	–15.8
Major salivary glands (C07–C08)	1.4	1.4	1.6	1.5	1.5	–4.9
Oropharynx (C09–C10)	2.6	2.3	2.0	2.5	2.3	15.0
Nasopharynx (C11)	0.9	0.9	1.2	0.9	0.8	–34.8
Hypopharynx (C12–C13)	2.0	2.0	2.0	1.6	1.2	–40.6
Pharynx, unspecified (C14)	0.4	0.6	0.6	0.6	0.6	–11.0
Nasal cavity, middle ear & sinuses (C30–C31)	0.9	1.1	1.4	0.9	0.9	–36.5
Larynx (C32)	8.7	7.5	7.1	6.7	5.1	–27.3
<i>Head and neck (C01–C14, C30–C32)</i>	23.8	22.6	22.9	21.3	18.9	–17.6
Oesophagus (C15)	7.0	7.9	7.9	7.9	8.2	3.1
Stomach (C16)	22.8	19.1	17.9	15.4	13.2	–26.1
Small intestine (C17)	0.9	1.1	1.3	1.6	2.1	64.3
Colon (C18)	42.2	44.6	46.7	46.0	45.2	–3.2
Rectum (C19–C20)	25.7	26.2	27.8	28.5	28.0	0.8
Anus (C21)	0.6	1.1	1.1	1.1	1.1	2.2
Liver (C22)	2.7	3.5	5.0	5.5	6.5	28.8
Gallbladder (C23–C24)	3.4	3.3	2.8	3.3	2.6	–6.2
Pancreas (C25)	11.5	11.4	11.1	11.2	11.3	2.0
Other thoracic organs (C37–C38)	0.5	0.5	0.6	0.6	0.5	–17.9
Bone & articular cartilage (C40–C41)	1.2	1.2	1.1	0.9	1.0	–5.5
Mesothelioma (C45)	2.1	3.9	4.4	5.1	5.7	28.3
Kaposi sarcoma (C46)	0.2	1.8	2.2	1.0	0.5	–76.0
Peritoneum & retroperitoneum (C48)	0.2	0.3	0.4	0.3	0.4	7.7
Other connective and soft tissue (C47, C49)	3.1	3.2	3.1	3.6	3.1	2.2
Breast (C50)	0.9	0.9	0.9	1.1	1.1	22.1
Penis (C60)	0.9	0.6	0.8	0.8	0.7	–11.5
Testis (C62)	4.1	4.2	5.2	6.0	6.5	25.0
Other male genital organs (C63)	0.1	0.1	0.4	0.3	0.3	–30.2
Kidney (C64)	8.8	10.1	12.2	13.9	13.6	11.0

(continued)

Table 2.16 (continued): Age-standardised rate of cancer incidence, males, Australia, selected years, 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
Bladder (C67)	30.1	26.8	24.5	20.8	18.3	–25.4
Other urinary organs (C65–C66, C68)	3.2	2.4	2.3	2.3	1.9	–17.1
Eye (C69)	1.3	1.3	1.9	1.8	1.5	–17.9
Brain (C71)	7.4	7.8	7.6	7.9	7.9	5.0
Other central nervous system (C70, C72)	0.4	0.5	0.4	0.3	0.4	–2.9
Thyroid (C73)	1.6	1.7	1.9	3.0	3.7	94.7
Other endocrine organs (C74–C75)	0.3	0.5	0.5	0.4	0.4	–16.9
Hodgkin lymphoma (C81)	2.7	2.6	2.2	2.3	2.5	12.7
<i>All lymphomas (C81–C85, C96)</i>	<i>17.0</i>	<i>19.8</i>	<i>22.9</i>	<i>23.0</i>	<i>24.1</i>	<i>5.2</i>
Immunoproliferative neoplasms (C88)	0.1	0.3	0.3	0.7	0.6	71.7
Myeloma (C90)	5.4	6.1	6.7	7.6	7.0	4.7
Lymphoid leukaemia (C91)	7.4	8.5	8.1	7.7	7.6	–5.4
Myeloid leukaemia (C92–C94)	6.5	7.8	7.9	7.9	7.6	–4.2
Leukaemia, unspecified (C95)	1.1	1.0	0.6	0.6	0.4	–31.5
<i>All leukaemias (C91–C95)</i>	<i>15.0</i>	<i>17.3</i>	<i>16.6</i>	<i>16.2</i>	<i>15.6</i>	<i>–5.8</i>
Polycythaemia rubra vera (D45)	0.3	0.3	0.8	1.1	2.1	166.3
Myelodysplastic syndromes (D46)	0.1	0.2	1.6	3.2	6.8	324.7
Other chronic myeloproliferative diseases (D47 ^(b))	0.3	0.7	0.9	1.9	1.7	97.7
Unknown primary site (C26, C39, C76, C80)	21.7	23.2	22.3	20.2	19.3	–13.4
All cancers (C00–C96^(a), D45–D47^(b))	469.9	496.1	581.9	543.6	548.2	–5.8

(a) Excludes non-melanocytic skin cancer (ICD-10 code C44).

(b) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.17: Age-standardised rate of cancer incidence, females, Australia, selected years, 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
NHPA cancers						
Colorectal (C18–C20)	50.4	49.4	52.2	51.9	51.1	–2.0
Lung, bronchus & trachea (C33–C34)	18.9	22.2	25.5	26.4	27.1	6.2
Melanoma of skin (C43)	28.3	36.3	35.5	37.2	37.9	6.8
Breast (C50)	80.8	89.5	105.3	114.5	111.8	6.1
Cervix (C53)	14.4	13.5	11.9	9.1	7.0	–41.3
Non-Hodgkin lymphoma (C82–C85, C96)	11.2	11.9	13.7	15.2	15.1	9.9
Other cancers						
Lip (C00)	1.5	2.3	2.6	3.0	2.5	–5.2
Tongue (C01–C02)	1.3	1.3	1.2	1.6	1.4	15.2
Mouth (C03–C06)	1.8	1.6	1.7	2.0	1.6	–2.4
Major salivary glands (C07–C08)	0.8	0.8	0.8	1.0	0.9	9.3
Oropharynx (C09–C10)	0.6	0.5	0.6	0.6	0.6	–9.0
Nasopharynx (C11)	0.4	0.2	0.4	0.3	0.3	–30.5
Hypopharynx (C12–C13)	0.3	0.4	0.3	0.2	0.1	–53.7
Pharynx, unspecified (C14)	0.2	0.1	0.2	0.1	0.1	–26.0
Nasal cavity, middle ear & sinuses (C30–C31)	0.5	0.4	0.5	0.5	0.4	–4.5
Larynx (C32)	0.9	0.8	0.6	0.6	0.6	–12.7
<i>Head and neck (C01–C14, C30–C32)</i>	<i>6.6</i>	<i>6.1</i>	<i>6.3</i>	<i>6.9</i>	<i>6.0</i>	<i>–4.3</i>
Oesophagus (C15)	3.5	4.4	4.0	3.7	3.4	–15.9
Stomach (C16)	10.4	8.1	7.1	6.7	5.8	–17.4
Small intestine (C17)	0.7	0.8	0.7	1.3	1.4	104.0
Colon (C18)	35.5	35.1	36.8	36.7	35.4	–3.9
Rectum (C19–C20)	14.9	14.3	15.3	15.2	15.7	2.4
Anus (C21)	0.9	1.1	1.0	1.3	1.3	39.8
Liver (C22)	0.7	0.9	1.5	1.6	2.5	68.1
Gallbladder (C23–C24)	3.8	3.9	3.5	3.7	3.1	–12.4
Pancreas (C25)	7.9	8.4	8.6	9.1	8.3	–3.1
Other thoracic organs (C37–C38)	0.1	0.3	0.3	0.4	0.2	–5.2
Bone & articular cartilage (C40–C41)	0.8	0.7	0.7	0.8	0.7	–7.7
Mesothelioma (C45)	0.2	0.4	0.6	0.6	1.0	60.3
Kaposi sarcoma (C46)	0.1	0.1	0.2	0.2	0.1	–60.4
Peritoneum & retroperitoneum (C48)	0.3	0.3	0.5	0.8	1.2	118.7
Other connective and soft tissue (C47, C49)	2.0	2.0	2.2	2.4	1.8	–15.1
Vulva (C51)	2.0	1.9	2.0	2.1	1.9	–3.0
Vagina (C52)	0.7	0.6	0.8	0.6	0.6	–21.5
Uterus, body (C54)	12.7	13.6	14.5	14.5	15.1	4.5
Uterus, unspecified (C55)	0.8	0.5	0.2	0.4	0.8	320.1

(continued)

Table 2.17 (continued): Age-standardised rate of cancer incidence, females, Australia, selected years, 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
Ovary (C56)	12.4	11.7	12.6	11.7	10.1	–19.4
Other female genital organs (C57)	0.3	0.3	0.5	0.4	0.5	13.4
Placenta (C58)	0.1	0.1	0.1	0.1	0.1	13.6
<i>Gynaecological (C51–C58)</i>	<i>43.4</i>	<i>42.2</i>	<i>42.5</i>	<i>39.0</i>	<i>36.2</i>	<i>–14.8</i>
Kidney (C64)	4.0	5.3	6.4	6.9	6.7	3.5
Bladder (C67)	7.8	7.7	6.3	5.9	5.1	–19.2
Other urinary organs (C65–C66, C68)	2.2	2.0	1.9	1.8	1.7	–10.0
Eye (C69)	1.1	1.0	1.0	1.1	1.0	–1.3
Brain (C71)	5.5	5.6	5.9	5.3	5.6	–3.9
Other central nervous system (C70, C72)	0.3	0.4	0.3	0.4	0.3	0.7
Thyroid (C73)	4.5	4.4	6.1	7.6	10.2	66.8
Other endocrine organs (C74–C75)	0.3	0.4	0.4	0.4	0.3	–18.3
Hodgkin lymphoma (C81)	1.6	1.7	1.7	1.9	1.8	4.3
<i>All lymphomas (C81–C85, C96)</i>	<i>12.8</i>	<i>13.6</i>	<i>15.5</i>	<i>17.1</i>	<i>16.9</i>	<i>9.3</i>
Immunoproliferative neoplasms (C88)	0.1	0.1	0.2	0.3	0.3	34.9
Myeloma (C90)	3.9	3.8	3.9	4.7	4.6	18.0
Lymphoid leukaemia (C91)	3.7	4.0	4.5	4.8	4.5	1.8
Myeloid leukaemia (C92–C94)	4.8	4.9	5.0	4.9	4.9	–1.7
Leukaemia, unspecified (C95)	0.6	0.6	0.5	0.4	0.3	–41.0
<i>All leukaemias (C91–C95)</i>	<i>9.0</i>	<i>9.5</i>	<i>9.9</i>	<i>10.0</i>	<i>9.8</i>	<i>–1.9</i>
Polycythaemia rubra vera (D45)	0.1	0.3	0.5	0.6	1.2	114.3
Myelodysplastic syndromes (D46)	0.0	0.2	0.7	1.6	3.4	367.2
Other chronic myeloproliferative diseases (D47 ^(b))	0.3	0.4	0.8	1.2	1.3	70.8
Unknown primary site (C26, C39, C76, C80)	16.8	16.4	16.0	15.4	14.7	–7.9
All cancers (C00–C96^(a), D45–D47^(b))	330.1	350.5	376.6	391.8	386.5	2.6

(a) Excludes non-melanocytic skin cancer (ICD-10 code C44).

(b) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Mortality in 2003

The 10 most common cancer deaths are shown in Table 2.18. Mortality data on a more comprehensive list of cancers are shown in tables 2.19–2.21.

Most common cancer deaths in 2003

- In persons the five most common cancer deaths were from lung cancer (6,988 deaths), colorectal cancer (4,372), unknown primary site (3,115), prostate cancer (2,837) and breast cancer (2,720). These five cancers accounted for 53% of all deaths from cancer.
- In males the five most common cancer deaths were from lung cancer (4,506 deaths), prostate cancer (2,837), colorectal cancer (2,382), unknown primary site (1,567), and pancreatic cancer (942). These five cancers accounted for 58% of all deaths from cancer in males.
- In females the five most common cancer deaths were from breast cancer (2,710 deaths), lung cancer (2,482), colorectal cancer (1,990), unknown primary site (1,548) and pancreatic cancer (940). These five cancers accounted for 58% of all deaths from cancer in females.

Risk of dying from cancer, based on 2003 data

- In 2003 the risk of dying from cancer for males was 1 in 8 before age 75 and 1 in 4 before age 85. The highest risk was for lung cancer with a 1 in 30 chance before age 75 and a 1 in 14 chance before age 85.
- In females the risk was 1 in 11 before age 75 and 1 in 6 before age 85. The highest risk to age 75 was for breast cancer (1 in 56) and to age 85 was for lung cancer (1 in 31).

Person-years of life lost due to premature death from cancer

- In 2003 Australians lost 261,348 person-years of life to age 75 and 523,665 years to age 85 due to premature death from cancer. The greatest contributor to this total was lung cancer, with 43,325 years to age 75 and 96,218 years to age 85.
- In 2003 males lost 140,573 person-years of life to age 75 and 292,668 years to age 85 due to premature death from cancer. The greatest contributor to this total was lung cancer, with 27,253 years to age 75 and 61,920 years to age 85.
- In 2003 females lost 120,775 person-years of life to age 75 and 230,998 years to age 85 due to premature death from cancer. The greatest contributor to this total was breast cancer, with 29,670 years to age 75 and 50,188 years to age 85.

Table 2.18: The 10 most common causes of death from cancer, Australia, 2003

Cancer site/type	Number	Per cent of all deaths	ASR(A)^(a)	ASR(W)^(a)	PYLL to age 75	PYLL to age 85
Persons						
Lung	6,988	18.4	34.2	23.5	43,325	96,218
Colorectal	4,372	11.5	21.3	14.3	27,118	57,003
Unknown site	3,115	8.2	15.1	9.7	15,148	33,860
Prostate	2,837	7.5	—	—	—	—
Breast	2,720	7.2	—	—	—	—
Pancreas	1,882	5.0	9.2	6.2	11,365	24,453
Lymphoma	1,539	4.1	7.5	5.1	11,318	21,860
Leukaemia	1,384	3.7	6.8	4.7	12,670	22,158
Stomach	1,169	3.1	5.7	3.8	7,860	15,750
Melanoma	1,146	3.0	5.6	4.0	11,585	20,228
<i>All cancers</i>	<i>37,907</i>	<i>100.0</i>	<i>184.9</i>	<i>125.1</i>	<i>261,348</i>	<i>523,665</i>
Males						
Lung	4,506	21.2	49.1	33.0	27,253	61,920
Prostate	2,837	13.4	34.1	19.6	6,285	20,928
Colorectal	2,382	11.2	26.2	17.5	15,743	33,530
Unknown site	1,567	7.4	17.8	11.3	8,775	19,283
Pancreas	942	4.4	10.2	7.0	6,625	13,873
Lymphoma	846	4.0	9.3	6.3	6,818	13,083
Leukaemia	795	3.7	8.8	6.0	7,663	13,570
Oesophagus	767	3.6	8.3	5.7	5,943	12,010
Melanoma	764	3.6	8.3	5.8	7,663	13,540
Stomach	686	3.2	7.6	5.1	4,853	9,865
<i>All cancers</i>	<i>21,238</i>	<i>100.0</i>	<i>236.5</i>	<i>156.0</i>	<i>140,573</i>	<i>292,668</i>
Females						
Breast	2,710	16.3	24.6	18.2	29,670	50,188
Lung	2,482	14.9	22.4	15.5	16,073	34,298
Colorectal	1,990	11.9	17.2	11.4	11,375	23,473
Unknown site	1,548	9.3	13.1	8.3	6,373	14,578
Pancreas	940	5.6	8.2	5.4	4,740	10,580
Ovary	781	4.7	7.1	5.1	6,690	12,510
Lymphoma	693	4.2	6.0	4.1	4,500	8,778
Leukaemia	589	3.5	5.1	3.6	5,008	8,588
Stomach	483	2.9	4.2	2.8	3,008	5,885
Brain	473	2.8	4.4	3.5	6,985	10,980
<i>All cancers</i>	<i>16,669</i>	<i>100.0</i>	<i>146.9</i>	<i>101.2</i>	<i>120,775</i>	<i>230,998</i>

(a) Age-standardised rates are expressed per 100,000 persons/males/females depending on the section of the table.

Source: National Mortality Database, AIHW.

Table 2.19: Cancer mortality in persons, Australia, 2003

Cancer site/type (ICD-10 codes)	Number	Per cent of total	ASR(A)	ASR(W)	PYLL to age 75	PYLL to age 85	M:F ratio (ASR(A))
Lip (C00)	11	0.0	0.1	0.0	63	123	4.0
Tongue (C01–C02)	178	0.5	0.9	0.6	1,853	3,290	2.5
Mouth (C03–C06)	116	0.3	0.6	0.4	948	1,800	1.9
Major salivary glands (C07–C08)	72	0.2	0.3	0.2	535	993	1.8
Oropharynx (C09–C10)	115	0.3	0.6	0.4	1,343	2,370	2.6
Nasopharynx (C11)	49	0.1	0.2	0.2	695	1,135	1.6
Hypopharynx (C12–C13)	57	0.2	0.3	0.2	538	1,033	9.3
Pharynx, unspecified (C14)	76	0.2	0.4	0.3	623	1,205	4.4
Nasal cavity, middle ear & sinuses (C30–C31)	33	0.1	0.2	0.1	240	470	1.7
Larynx (C32)	223	0.6	1.1	0.8	1,645	3,458	8.5
<i>Head and neck (C01–C14, C30–C32)</i>	<i>919</i>	<i>2.4</i>	<i>4.5</i>	<i>3.2</i>	<i>8,418</i>	<i>15,753</i>	<i>3.2</i>
Oesophagus (C15)	1,130	3.0	5.5	3.8	7,505	15,625	2.7
Stomach (C16)	1,169	3.1	5.7	3.8	7,860	15,750	1.8
Small intestine (C17)	89	0.2	0.4	0.3	775	1,440	1.5
Colon (C18)	3,012	7.9	14.7	9.7	17,778	37,950	1.4
Rectum (C19–C20)	1,360	3.6	6.6	4.5	9,340	19,053	1.8
<i>Colorectal (C18–C20)</i>	<i>4,372</i>	<i>11.5</i>	<i>21.3</i>	<i>14.3</i>	<i>27,118</i>	<i>57,003</i>	<i>1.5</i>
Anus (C21)	57	0.2	0.3	0.2	405	783	1.2
Liver (C22)	892	2.4	4.4	3.1	7,073	13,900	2.5
Gallbladder (C23–C24)	290	0.8	1.4	1.0	1,793	3,803	0.8
Pancreas (C25)	1,882	5.0	9.2	6.2	11,365	24,453	1.3
Lung, bronchus & trachea (C33–C34)	6,988	18.4	34.2	23.5	43,325	96,218	2.2
Other thoracic organs (C37–C38)	36	0.1	0.2	0.1	350	620	2.9
Bone & articular cartilage (C40–C41)	100	0.3	0.5	0.4	2,815	3,675	1.5
Melanoma of skin (C43)	1,146	3.0	5.6	4.0	11,585	20,228	2.4
Non-melanoma of skin (C44)	390	1.0	1.9	1.1	1,493	3,458	2.9
Mesothelioma (C45)	510	1.3	2.5	1.7	2,738	6,440	6.3
Kaposi sarcoma (C46)	5	0.0	0.0	0.0	3	18	2.7
Peritoneum & retroperitoneum (C48)	59	0.2	0.3	0.2	400	833	0.2
Other connective and soft tissue (C47, C49)	186	0.5	0.9	0.7	2,973	4,485	1.6
Breast (C50)	2,720	7.2	—	—	—	—	0.004
Vulva (C51)	47	0.1	—	—	—	—	—
Vagina (C52)	29	0.1	—	—	—	—	—
Cervix (C53)	239	0.6	—	—	—	—	—
Uterus, body (C54)	216	0.6	—	—	—	—	—
Uterus, unspecified (C55)	81	0.2	—	—	—	—	—
Ovary (C56)	781	2.1	—	—	—	—	—
Other female genital organs (C57)	22	0.1	—	—	—	—	—

(continued)

Table 2.19 (continued): Cancer mortality in persons, Australia, 2003

Cancer site/type (ICD-10 codes)	Number	Per cent of total	ASR(A)	ASR(W)	PYLL to age 75	PYLL to age 85	M:F ratio (ASR(A))
Placenta (C58)	0	0.0	—	—	—	—	—
<i>Gynaecological (C51–C58)</i>	<i>1,415</i>	<i>3.7</i>	—	—	—	—	—
Penis (C60)	15	0.0	—	—	—	—	—
Prostate (C61)	2,837	7.5	—	—	—	—	—
Testis (C62)	17	0.0	—	—	—	—	—
Other male genital organs (C63)	3	0.0	—	—	—	—	—
Kidney (C64)	798	2.1	3.9	2.7	5,813	11,683	2.0
Bladder (C67)	871	2.3	4.2	2.6	2,750	7,498	3.0
Other urinary organs (C65–C66, C68)	70	0.2	0.3	0.2	203	623	1.2
Eye (C69)	37	0.1	0.2	0.1	300	553	1.4
Brain (C71)	1,111	2.9	5.5	4.3	17,335	26,968	1.5
Other central nervous system (C70, C72)	22	0.1	0.1	0.1	538	735	1.1
Thyroid (C73)	86	0.2	0.4	0.3	373	928	1.2
Other endocrine organs (C74–C75)	40	0.1	0.2	0.2	1,093	1,453	1.0
Hodgkin lymphoma (C81)	67	0.2	0.3	0.2	975	1,448	1.3
Non-Hodgkin lymphoma (C82–C85, C96)	1,472	3.9	7.2	4.9	10,343	20,413	1.6
<i>All lymphomas (C81–C85, C96)</i>	<i>1,539</i>	<i>4.1</i>	<i>7.5</i>	<i>5.1</i>	<i>11,318</i>	<i>21,860</i>	<i>1.5</i>
Immunoproliferative neoplasms (C88)	34	0.1	0.2	0.1	140	343	1.8
Myeloma (C90)	742	2.0	3.6	2.3	3,683	8,350	1.5
Lymphoid leukaemia (C91)	444	1.2	2.2	1.5	4,720	7,693	1.9
Myeloid leukaemia (C92–C94)	864	2.3	4.2	2.9	7,233	13,283	1.6
Leukaemia, unspecified (C95)	76	0.2	0.4	0.3	718	1,183	1.9
<i>All leukaemias (C91–C95)</i>	<i>1,384</i>	<i>3.7</i>	<i>6.8</i>	<i>4.7</i>	<i>12,670</i>	<i>22,158</i>	<i>1.7</i>
Polycythaemia rubra vera (D45)	25	0.1	0.1	0.1	90	250	1.4
Myelodysplastic syndromes (D46)	302	0.8	1.5	0.8	528	1,728	2.1
Other chronic myeloproliferative diseases (D47 ^(a))	124	0.3	0.6	0.4	353	913	1.9
Multiple primary cancers (C97)	369	1.0	1.8	1.1	1,585	3,885	2.1
Unknown primary site (C26, C39, C76–C80)	3,115	8.2	15.1	9.7	15,148	33,860	1.4
All cancers (C00–C97, D45–D47^(a))	37,907	100.0	184.9	125.1	261,348	523,665	1.6

(a) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.20: Cancer mortality in males, Australia, 2003

Cancer site/type (ICD-10 codes)	Number	Per cent of total	ASR(A)	ASR(W)	PYLL to age 75	PYLL to age 85
Lip (C00)	8	0.0	0.1	0.1	50	100
Tongue (C01–C02)	120	0.6	1.3	0.9	1,340	2,405
Mouth (C03–C06)	71	0.3	0.7	0.6	835	1,425
Major salivary glands (C07–C08)	41	0.2	0.5	0.3	293	580
Oropharynx (C09–C10)	81	0.4	0.8	0.6	955	1,690
Nasopharynx (C11)	29	0.1	0.3	0.2	463	725
Hypopharynx (C12–C13)	51	0.2	0.5	0.4	453	888
Pharynx, unspecified (C14)	59	0.3	0.6	0.5	558	1,053
Nasal cavity, middle ear & sinuses (C30–C31)	19	0.1	0.2	0.1	138	270
Larynx (C32)	196	0.9	2.1	1.5	1,460	3,075
<i>Head and neck (C01–C14, C30–C32)</i>	<i>667</i>	<i>3.1</i>	<i>7.1</i>	<i>5.1</i>	<i>6,493</i>	<i>12,110</i>
Oesophagus (C15)	767	3.6	8.3	5.7	5,943	12,010
Stomach (C16)	686	3.2	7.6	5.1	4,853	9,865
Small intestine (C17)	49	0.2	0.5	0.4	425	790
Colon (C18)	1,571	7.4	17.4	11.5	9,923	21,438
Rectum (C19–C20)	811	3.8	8.8	6.0	5,820	12,093
<i>Colorectal (C18–C20)</i>	<i>2,382</i>	<i>11.2</i>	<i>26.2</i>	<i>17.5</i>	<i>15,743</i>	<i>33,530</i>
Anus (C21)	28	0.1	0.3	0.2	215	420
Liver (C22)	604	2.8	6.5	4.5	5,173	10,073
Gallbladder (C23–C24)	113	0.5	1.2	0.8	818	1,685
Pancreas (C25)	942	4.4	10.2	7.0	6,625	13,873
Lung, bronchus & trachea (C33–C34)	4,506	21.2	49.1	33.0	27,253	61,920
Other thoracic organs (C37–C38)	25	0.1	0.3	0.2	285	488
Bone & articular cartilage (C40–C41)	59	0.3	0.6	0.5	1,668	2,180
Melanoma of skin (C43)	764	3.6	8.3	5.8	7,663	13,540
Non-melanoma of skin (C44)	258	1.2	3.0	1.9	1,258	2,790
Mesothelioma (C45)	426	2.0	4.7	3.1	2,203	5,303
Kaposi sarcoma (C46)	3	0.0	0.0	0.0	3	13
Peritoneum & retroperitoneum (C48)	8	0.0	0.1	0.1	68	128
Other connective and soft tissue (C47, C49)	108	0.5	1.2	0.9	1,718	2,603
Breast (C50)	10	0.0	0.1	0.1	100	175
Penis (C60)	15	0.1	0.2	0.1	185	298
Prostate (C61)	2,837	13.4	34.1	19.6	6,285	20,928
Testis (C62)	17	0.1	0.2	0.2	500	668
Other male genital organs (C63)	3	0.0	0.0	0.0	38	68
Kidney (C64)	492	2.3	5.3	3.7	4,150	8,123
Bladder (C67)	594	2.8	7.0	4.2	2,058	5,488
Other urinary organs (C65–C66, C68)	32	0.2	0.4	0.2	103	290

(continued)

Table 2.20 (continued): Cancer mortality in males, Australia, 2003

Cancer site/type (ICD-10 codes)	Number	Per cent of total	ASR(A)	ASR(W)	PYLL to age 75	PYLL to age 85
Eye (C69)	19	0.1	0.2	0.1	203	353
Brain (C71)	638	3.0	6.6	5.2	10,350	15,988
Other central nervous system (C70, C72)	11	0.1	0.1	0.1	320	428
Thyroid (C73)	42	0.2	0.5	0.3	198	520
Other endocrine organs (C74–C75)	19	0.1	0.2	0.2	543	718
Hodgkin lymphoma (C81)	34	0.2	0.4	0.3	460	730
Non-Hodgkin lymphoma (C82–C85, C96)	812	3.8	9.0	6.1	6,358	12,353
<i>All lymphomas (C81–C85, C96)</i>	<i>846</i>	<i>4.0</i>	<i>9.3</i>	<i>6.3</i>	<i>6,818</i>	<i>13,083</i>
Immunoproliferative neoplasms (C88)	19	0.1	0.2	0.1	83	208
Myeloma (C90)	399	1.9	4.5	2.9	2,240	4,918
Lymphoid leukaemia (C91)	263	1.2	2.9	2.0	2,988	5,008
Myeloid leukaemia (C92–C94)	487	2.3	5.4	3.7	4,238	7,845
Leukaemia, unspecified (C95)	45	0.2	0.5	0.3	438	718
<i>All leukaemias (C91–C95)</i>	<i>795</i>	<i>3.7</i>	<i>8.8</i>	<i>6.0</i>	<i>7,663</i>	<i>13,570</i>
Polycythaemia rubra vera (D45)	13	0.1	0.2	0.1	48	120
Myelodysplastic syndromes (D46)	173	0.8	2.1	1.2	350	1,073
Other chronic myeloproliferative diseases (D47 ^(a))	69	0.3	0.8	0.5	265	688
Multiple primary cancers (C97)	225	1.1	2.6	1.6	853	2,270
Unknown primary site (C26, C39, C76–C80)	1,567	7.4	17.8	11.3	8,775	19,283
All cancers (C00–C97, D45–D47^(a))	21,238	100.0	236.5	156.0	140,573	292,668

(a) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.21: Cancer mortality in females, Australia, 2003

Cancer site/type (ICD-10 codes)	Number	Per cent of total	ASR(A)	ASR(W)	PYLL to age 75	PYLL to age 85
Lip (C00)	3	0.0	0.0	0.0	13	23
Tongue (C01–C02)	58	0.3	0.5	0.4	513	885
Mouth (C03–C06)	45	0.3	0.4	0.2	113	375
Major salivary glands (C07–C08)	31	0.2	0.3	0.2	243	413
Oropharynx (C09–C10)	34	0.2	0.3	0.2	388	680
Nasopharynx (C11)	20	0.1	0.2	0.1	233	410
Hypopharynx (C12–C13)	6	0.0	0.1	0.0	85	145
Pharynx, unspecified (C14)	17	0.1	0.1	0.1	65	153
Nasal cavity, middle ear & sinuses (C30–C31)	14	0.1	0.1	0.1	103	200
Larynx (C32)	27	0.2	0.2	0.2	185	383
<i>Head and neck (C01–C14, C30–C32)</i>	<i>252</i>	<i>1.5</i>	<i>2.2</i>	<i>1.6</i>	<i>1,925</i>	<i>3,643</i>
Oesophagus (C15)	363	2.2	3.1	2.0	1,563	3,615
Stomach (C16)	483	2.9	4.2	2.8	3,008	5,885
Small intestine (C17)	40	0.2	0.4	0.3	350	650
Colon (C18)	1,441	8.6	12.5	8.2	7,855	16,513
Rectum (C19–C20)	549	3.3	4.8	3.2	3,520	6,960
<i>Colorectal (C18–C20)</i>	<i>1,990</i>	<i>11.9</i>	<i>17.2</i>	<i>11.4</i>	<i>11,375</i>	<i>23,473</i>
Anus (C21)	29	0.2	0.3	0.2	190	363
Liver (C22)	288	1.7	2.5	1.7	1,900	3,828
Gallbladder (C23–C24)	177	1.1	1.5	1.0	975	2,118
Pancreas (C25)	940	5.6	8.2	5.4	4,740	10,580
Lung, bronchus & trachea (C33–C34)	2,482	14.9	22.4	15.5	16,073	34,298
Other thoracic organs (C37–C38)	11	0.1	0.1	0.1	65	133
Bone & articular cartilage (C40–C41)	41	0.2	0.4	0.4	1,148	1,495
Melanoma of skin (C43)	382	2.3	3.4	2.5	3,923	6,688
Non-melanoma of skin (C44)	132	0.8	1.0	0.6	235	668
Mesothelioma (C45)	84	0.5	0.8	0.5	535	1,138
Kaposi sarcoma (C46)	2	0.0	0.0	0.0	0	5
Peritoneum & retroperitoneum (C48)	51	0.3	0.5	0.3	333	705
Other connective and soft tissue (C47, C49)	78	0.5	0.7	0.6	1,255	1,883
Breast (C50)	2,710	16.3	24.6	18.2	29,670	50,188
Vulva (C51)	47	0.3	0.4	0.2	180	403
Vagina (C52)	29	0.2	0.2	0.1	105	253
Cervix (C53)	239	1.4	2.2	1.7	3,420	5,338
Uterus, body (C54)	216	1.3	1.9	1.4	1,540	3,118
Uterus, unspecified (C55)	81	0.5	0.7	0.5	510	1,010
Ovary (C56)	781	4.7	7.1	5.1	6,690	12,510
Other female genital organs (C57)	22	0.1	0.2	0.1	158	328

(continued)

Table 2.21 (continued): Cancer mortality in females, Australia, 2003

Cancer site/type (ICD-10 codes)	Number	Per cent of total	ASR(A)	ASR(W)	PYLL to age 75	PYLL to age 85
Placenta (C58)	0	0.0	0.0	0.0	0	0
<i>Gynaecological (C51–C58)</i>	<i>1,415</i>	<i>8.5</i>	<i>12.7</i>	<i>9.1</i>	<i>12,603</i>	<i>22,958</i>
Kidney (C64)	306	1.8	2.7	1.8	1,663	3,560
Bladder (C67)	277	1.7	2.3	1.4	693	2,010
Other urinary organs (C65–C66, C68)	38	0.2	0.3	0.2	100	333
Eye (C69)	18	0.1	0.2	0.1	98	200
Brain (C71)	473	2.8	4.4	3.5	6,985	10,980
Other central nervous system (C70, C72)	11	0.1	0.1	0.1	218	308
Thyroid (C73)	44	0.3	0.4	0.2	175	408
Other endocrine organs (C74–C75)	21	0.1	0.2	0.2	550	735
Hodgkin lymphoma (C81)	33	0.2	0.3	0.2	515	718
Non-Hodgkin lymphoma (C82–C85, C96)	660	4.0	5.7	3.8	3,985	8,060
<i>All lymphomas (C81–C85, C96)</i>	<i>693</i>	<i>4.2</i>	<i>6.0</i>	<i>4.1</i>	<i>4,500</i>	<i>8,778</i>
Immunoproliferative neoplasms (C88)	15	0.1	0.1	0.1	58	135
Myeloma (C90)	343	2.1	2.9	1.9	1,443	3,433
Lymphoid leukaemia (C91)	181	1.1	1.5	1.1	1,733	2,685
Myeloid leukaemia (C92–C94)	377	2.3	3.3	2.3	2,995	5,438
Leukaemia, unspecified (C95)	31	0.2	0.3	0.2	280	465
<i>All leukaemias (C91–C95)</i>	<i>589</i>	<i>3.5</i>	<i>5.1</i>	<i>3.6</i>	<i>5,008</i>	<i>8,588</i>
Polycythaemia rubra vera (D45)	12	0.1	0.1	0.1	43	130
Myelodysplastic syndromes (D46)	129	0.8	1.0	0.6	178	655
Other chronic myeloproliferative diseases (D47 ^(a))	55	0.3	0.4	0.2	88	225
Multiple primary cancers (C97)	144	0.9	1.2	0.8	733	1,615
Unknown primary site (C26, C39, C76–C80)	1,548	9.3	13.1	8.3	6,373	14,578
All cancers (C00–C97, D45–D47^(a))	16,669	100.0	146.9	101.2	120,775	230,998

(a) Only includes D47.1 and D47.3.

Source: National Cancer Statistics Clearing House, AIHW.

Mortality trends 1983–2003

Numbers

The numbers of deaths from cancer over the period 1983–2003 are shown in tables 2.22–2.24. Note that cancers for which the numbers are small are subject to large percentage fluctuations from one year to the next. Therefore the following comments are restricted to NHPA cancers and cancers for which the number of deaths in 1993 was at least 500 persons.

- The total number of deaths from cancer in 2003 was 15% higher than in 1993 (14% for males, 17% for females) compared with a 9.1% increase in deaths from all causes over the same period.
- Among the NHPA cancers the number of deaths from cervical cancer decreased by 25% and those from colorectal cancer decreased by 0.6% (up 2.6% in males, down 4.1% in females). The number of deaths increased for melanoma (up 34%: 31% in males, 40% in females), prostate cancer (12%), non-Hodgkin lymphoma (10%: 13% in males, 6.8% in females), lung cancer (up 10% overall: down 0.4% in males but up 36% in females) and breast cancer in females (up 3.8%).
- Among other cancers in males the number of stomach cancer deaths decreased by 13%. The number of deaths increased for oesophageal cancer (up 39%), cancers of unknown primary site (39%), pancreatic cancer (25%), leukaemia (20%), brain cancer (19%) and bladder cancer (11%).
- Among other cancers in females there were no decreases in the number of deaths. The number of deaths increased for cancers of unknown primary site (up 36%), pancreatic cancer (30%), ovarian cancer (11%) and leukaemia (8.3%).

Age-standardised rates

Age-standardised death rates (against the Australian 2001 Standard Population) over the period 1983–2003 are shown in tables 2.25–2.27. Note that cancers for which the rates are small are subject to large percentage fluctuations from one year to the next. Therefore the following comments are restricted to cancers for which the 1993 rate was at least 5.0 per 100,000.

- The death rate for all cancers was 12% lower in 2003 than in 1993.
- Among the NHPA cancers the largest decrease in death rate from 1993 to 2003 was for cervical cancer (down 41%), followed by colorectal cancer (25%: 24% in males, 27% in females), prostate cancer (22%), breast cancer in females (20%), non-Hodgkin lymphoma (15%: 13% in males, 19% in females) and lung cancer (14%: down 24% in males but up 6.7% in females). Among the NHPA cancers the only increase in death rate from 1993 to 2003 was for melanoma of the skin (up 4.4%: 3.3% in males, 9.1% in females).
- In other cancers in males, the death rate decreased by more than 10% for stomach cancer (down 37%), bladder cancer (22%) and leukaemia (12%). There were no increases of more than 10%.
- In other cancers in females, the death rate decreased by more than 10% for stomach cancer (down 17%), leukaemia (16%) and ovarian cancer (12%). There were no increases of more than 10%.

Table 2.22: Deaths from cancer, persons, Australia, selected years 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
NHPA cancers						
Colorectal (C18–C20)	3,758	4,112	4,398	4,599	4,372	–0.6
Lung, bronchus & trachea (C33–C34)	5,433	6,115	6,351	6,764	6,988	10.0
Melanoma of skin (C43)	623	771	853	966	1,146	34.3
Non-Hodgkin lymphoma (C82–C85, C96)	844	1,061	1,336	1,509	1,472	10.2
Other cancers						
Lip (C00)	17	16	13	12	11	–15.4
Tongue (C01–C02)	146	167	172	168	178	3.5
Mouth (C03–C06)	97	117	111	127	116	4.5
Major salivary glands (C07–C08)	48	60	62	73	72	16.1
Oropharynx (C09–C10)	81	112	135	117	115	–14.8
Nasopharynx (C11)	55	55	60	54	49	–18.3
Hypopharynx (C12–C13)	57	71	73	58	57	–21.9
Pharynx, unspecified (C14)	13	27	35	36	76	117.1
Nasal cavity, middle ear & sinuses (C30–C31)	40	25	48	53	33	–31.3
Larynx (C32)	203	211	247	197	223	–9.7
<i>Head and neck (C01–C14, C30–C32)</i>	<i>740</i>	<i>845</i>	<i>943</i>	<i>883</i>	<i>919</i>	<i>–2.5</i>
Oesophagus (C15)	585	785	829	976	1,130	36.3
Stomach (C16)	1,456	1,376	1,232	1,195	1,169	–5.1
Small intestine (C17)	52	61	61	88	89	45.9
Colon (C18)	2,796	3,086	3,289	3,394	3,012	–8.4
Rectum (C19–C20)	962	1,026	1,109	1,205	1,360	22.6
Anus (C21)	34	32	29	44	57	96.6
Liver (C22)	325	374	501	631	892	78.0
Gallbladder (C23–C24)	330	310	297	349	290	–2.4
Pancreas (C25)	1,141	1,259	1,477	1,618	1,882	27.4
Other thoracic organs ex. pleura (C37–C38, ex. C38.4) ^(a)	22	38	27	43	36	33.3
Bone & articular cartilage (C40–C41)	98	93	101	92	100	–1.0
Non-melanoma of skin (C44)	213	210	374	358	390	4.3
Mesothelioma and other pleura (C45, C38.4) ^(a)	92	130	187	403	510	172.7
Kaposi sarcoma (C46)	0	0	0	2	5	—
Peritoneum & retroperitoneum (C48)	41	31	50	66	59	18.0
Other connective and soft tissue (C47, C49)	145	166	203	184	186	–8.4
Breast (C50)	2,053	2,384	2,626	2,560	2,720	3.6
Vulva (C51)	34	50	51	61	47	–7.8
Vagina (C52)	19	16	23	22	29	26.1
Cervix (C53)	343	345	318	260	239	–24.8

(continued)

Table 2.22 (continued): Deaths from cancer, persons, Australia, selected years 1983–2003

Cancer site/type	1983	1988	1993	1998	2003	Per cent change 93–03
Uterus, body (C54)	206	194	223	225	216	–3.1
Uterus, unspecified (C55)	38	33	30	30	81	170.0
Ovary (C56)	595	602	704	750	781	10.9
Other female genital organs (C57)	13	10	17	32	22	29.4
Placenta (C58)	2	0	1	0	0	–100.0
<i>Gynaecological (C51–C58)</i>	<i>1,250</i>	<i>1,250</i>	<i>1,367</i>	<i>1,380</i>	<i>1,415</i>	<i>3.5</i>
Penis (C60)	12	11	10	12	15	50.0
Prostate (C61)	1,397	1,883	2,539	2,570	2,837	11.7
Testis (C62)	45	33	16	22	17	6.3
Other male genital organs (C63)	2	2	2	3	3	50.0
Kidney (C64)	539	621	699	771	798	14.2
Bladder (C67)	583	708	766	798	871	13.7
Other urinary organs (C65–C66, C68)	39	53	47	67	70	48.9
Eye (C69)	30	36	29	27	37	27.6
Brain (C71)	754	847	915	1,010	1,111	21.4
Other central nervous system (C70, C72)	19	18	18	13	22	22.2
Thyroid (C73)	76	69	78	66	86	10.3
Other endocrine organs (C74–C75)	45	46	51	49	40	–21.6
Hodgkin lymphoma (C81)	93	107	83	52	67	–19.3
<i>All lymphomas (C81–C85, C96)</i>	<i>937</i>	<i>1,168</i>	<i>1,419</i>	<i>1,561</i>	<i>1,539</i>	<i>8.5</i>
Immunoproliferative neoplasms (C88)	17	28	31	28	34	9.7
Myeloma (C90)	350	469	546	615	742	35.9
Lymphoid leukaemia (C91)	311	369	391	420	444	13.6
Myeloid leukaemia (C92–C94)	593	631	782	851	864	10.5
Leukaemia, unspecified (C95)	74	64	34	61	76	123.5
<i>All leukaemias (C91–C95)</i>	<i>978</i>	<i>1,064</i>	<i>1,207</i>	<i>1,332</i>	<i>1,384</i>	<i>14.7</i>
Polycythaemia rubra vera (D45)	30	40	25	24	25	0.0
Myelodysplastic syndromes and chronic myeloproliferative disorders (D46–D47 ^{(b)(c)})	24	65	243	374	426	75.3
Multiple primary cancers (C97) ^(d)	0	0	0	361	369	—
Unknown primary site (C26, C39, C76–C80)	1,476	2,016	2,270	2,498	3,115	37.2
All cancers (C00–C97, D45–D47^(b))	25,761	29,535	32,830	35,414	37,907	15.5

(a) The ICD-10 codes C38.4 and C45 are inseparable in ICD-9 coding (used for deaths registered in 1996 and before).

(b) Only includes D47.1 and D47.3.

(c) The ICD-10 codes D46 and D47 are inseparable in ICD-9 coding (used for deaths registered in 1996 and before).

(d) The ICD-10 code C97 had no equivalent in ICD-9 coding (used for deaths registered in 1996 and before).

Source: National Mortality Database, AIHW.

Table 2.23: Deaths from cancer, males, Australia, selected years 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
NHPA cancers						
Colorectal (C18–C20)	1,933	2,190	2,322	2,465	2,382	2.6
Lung, bronchus & trachea (C33–C34)	4,255	4,595	4,523	4,714	4,506	–0.4
Melanoma of skin (C43)	362	479	581	623	764	31.5
Prostate (C61)	1,397	1,883	2,539	2,570	2,837	11.7
Non-Hodgkin lymphoma (C82–C85, C96)	448	585	719	756	812	12.9
Other cancers						
Lip (C00)	14	12	12	7	8	–33.3
Tongue (C01–C02)	107	124	116	128	120	3.4
Mouth (C03–C06)	66	77	66	79	71	7.6
Major salivary glands (C07–C08)	32	37	42	48	41	–2.4
Oropharynx (C09–C10)	68	87	102	89	81	–20.6
Nasopharynx (C11)	45	41	42	39	29	–31.0
Hypopharynx (C12–C13)	42	58	57	46	51	–10.5
Pharynx, unspecified (C14)	9	21	26	28	59	126.9
Nasal cavity, middle ear & sinuses (C30–C31)	24	15	31	36	19	–38.7
Larynx (C32)	184	185	219	184	196	–10.5
<i>Head and neck (C01–C14, C30–C32)</i>	<i>577</i>	<i>645</i>	<i>701</i>	<i>677</i>	<i>667</i>	<i>–4.9</i>
Oesophagus (C15)	374	505	550	646	767	39.5
Stomach (C16)	892	861	786	765	686	–12.7
Small intestine (C17)	31	31	26	56	49	88.5
Colon (C18)	1,358	1,552	1,682	1,742	1,571	–6.6
Rectum (C19–C20)	575	638	640	723	811	26.7
Anus (C21)	11	14	18	19	28	55.6
Liver (C22)	225	244	354	425	604	70.6
Gallbladder (C23–C24)	120	115	108	137	113	4.6
Pancreas (C25)	636	669	754	813	942	24.9
Other thoracic organs ex. pleura (C37–C38, ex. C38.4) ^(a)	15	26	17	13	18	5.9
Bone & articular cartilage (C40–C41)	59	49	53	54	59	11.3
Non-melanoma of skin (C44)	151	158	270	242	258	–4.4
Mesothelioma and other pleura (C45, C38.4) ^(a)	77	111	165	370	433	162.4
Kaposi sarcoma (C46)	0	0	0	2	3	—
Peritoneum & retroperitoneum (C48)	17	12	25	23	8	–68.0
Other connective and soft tissue (C47, C49)	83	94	102	97	108	5.9
Breast (C50)	13	23	15	19	10	–33.3
Penis (C60)	12	11	10	12	15	50.0
Testis (C62)	45	33	16	22	17	6.3

(continued)

Table 2.23 (continued): Deaths from cancer, males, Australia, selected years 1983–2003

Cancer site/type	1983	1988	1993	1998	2003	Per cent change 93–03
Other male genital organs (C63)	2	2	2	3	3	50.0
Kidney (C64)	327	358	382	450	492	28.8
Bladder (C67)	414	502	533	553	594	11.4
Other urinary organs (C65–C66, C68)	21	20	24	37	32	33.3
Eye (C69)	18	20	12	16	19	58.3
Brain (C71)	437	484	534	569	638	19.5
Other central nervous system (C70, C72)	9	11	11	8	11	0.0
Thyroid (C73)	22	18	30	37	42	40.0
Other endocrine organs (C74–C75)	25	24	31	25	19	–38.7
Hodgkin lymphoma (C81)	49	66	59	32	34	–42.4
<i>All lymphomas (C81–C85, C96)</i>	<i>497</i>	<i>651</i>	<i>778</i>	<i>788</i>	<i>846</i>	<i>8.7</i>
Immunoproliferative neoplasms (C88)	14	18	22	20	19	–13.6
Myeloma (C90)	189	225	303	331	399	31.7
Lymphoid leukaemia (C91)	195	226	215	247	263	22.3
Myeloid leukaemia (C92–C94)	304	352	428	490	487	13.8
Leukaemia, unspecified (C95)	38	35	20	35	45	125.0
<i>All leukaemias (C91–C95)</i>	<i>537</i>	<i>613</i>	<i>663</i>	<i>772</i>	<i>795</i>	<i>19.9</i>
Polycythaemia rubra vera (D45)	12	15	14	13	13	–7.1
Myelodysplastic syndromes and chronic myeloproliferative disorders (D46–D47 ^{(b)(c)})	12	35	140	215	242	72.9
Multiple primary cancers (C97) ^(d)	0	0	0	227	225	—
Unknown primary site (C26, C39, C76–C80)	729	1,063	1,129	1,256	1,567	38.8
All cancers (C00–C97, D45–D47^(b))	14,564	16,819	18,555	20,091	21,238	14.5

(a) The ICD-10 codes C38.4 and C45 are inseparable in ICD-9 coding (used for deaths registered in 1996 and before).

(b) Only includes D47.1 and D47.3.

(c) The ICD-10 codes D46 and D47 are inseparable in ICD-9 coding (used for deaths registered in 1996 and before).

(d) The ICD-10 code C97 had no equivalent in ICD-9 coding (used for deaths registered in 1996 and before).

Source: National Mortality Database, AIHW.

Table 2.24: Deaths from cancer, females, Australia, selected years 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
NHPA cancers						
Colorectal (C18–C20)	1,825	1,923	2,076	2,134	1,990	–4.1
Lung, bronchus & trachea (C33–C34)	1,178	1,521	1,828	2,050	2,482	35.8
Melanoma of skin (C43)	261	293	272	343	382	40.4
Breast (C50)	2,040	2,361	2,611	2,541	2,710	3.8
Cervix (C53)	343	345	318	260	239	–24.8
Non-Hodgkin lymphoma (C82–C85, C96)	396	476	618	753	660	6.8
Other cancers						
Lip (C00)	3	4	1	5	3	200.0
Tongue (C01–C02)	39	44	56	40	58	3.6
Mouth (C03–C06)	31	40	45	48	45	0.0
Major salivary glands (C07–C08)	16	23	20	25	31	55.0
Oropharynx (C09–C10)	13	25	33	28	34	3.0
Nasopharynx (C11)	10	14	18	15	20	11.1
Hypopharynx (C12–C13)	15	13	16	12	6	–62.5
Pharynx, unspecified (C14)	4	6	9	8	17	88.9
Nasal cavity, middle ear & sinuses (C30–C31)	16	10	17	17	14	–17.6
Larynx (C32)	19	26	28	13	27	–3.6
<i>Head and neck (C01–C14, C30–C32)</i>	<i>163</i>	<i>201</i>	<i>242</i>	<i>206</i>	<i>252</i>	<i>4.1</i>
Oesophagus (C15)	211	280	279	330	363	30.1
Stomach (C16)	564	515	446	430	483	8.3
Small intestine (C17)	21	30	35	32	40	14.3
Colon (C18)	1,438	1,535	1,607	1,652	1,441	–10.3
Rectum (C19–C20)	387	388	469	482	549	17.1
Anus (C21)	23	18	11	25	29	163.6
Liver (C22)	100	130	147	206	288	95.9
Gallbladder (C23–C24)	210	195	190	212	177	–6.8
Pancreas (C25)	505	590	723	805	940	30.0
Other thoracic organs ex. pleura (C37–C38, ex. C38.4) ^(a)	7	12	10	14	9	–10.0
Bone & articular cartilage (C40–C41)	39	44	48	38	41	–14.6
Non-melanoma of skin (C44)	62	52	104	116	132	26.9
Mesothelioma and other pleura (C45, C38.4) ^(a)	15	19	22	49	86	290.9
Kaposi sarcoma (C46)	0	0	0	0	2	—
Peritoneum & retroperitoneum (C48)	24	19	25	43	51	104.0
Other connective and soft tissue (C47, C49)	62	72	102	87	78	–23.5
Vulva (C51)	34	50	51	61	47	–7.8
Vagina (C52)	19	16	23	22	29	26.1

(continued)

Table 2.24 (continued): Deaths from cancer, females, Australia, selected years 1983–2003

Cancer site/type	1983	1988	1993	1998	2003	Per cent change 93–03
Uterus, body (C54)	206	194	223	225	216	–3.1
Uterus, unspecified (C55)	38	33	30	30	81	170.0
Ovary (C56)	595	602	704	750	781	10.9
Other female genital organs (C57)	13	10	17	32	22	29.4
Placenta (C58)	2	0	1	0	0	–100.0
<i>Gynaecological (C51–C58)</i>	<i>1,250</i>	<i>1,250</i>	<i>1,367</i>	<i>1,380</i>	<i>1,415</i>	<i>3.5</i>
Kidney (C64)	212	263	317	321	306	–3.5
Bladder (C67)	169	206	233	245	277	18.9
Other urinary organs (C65–C66, C68)	18	33	23	30	38	65.2
Eye (C69)	12	16	17	11	18	5.9
Brain (C71)	317	363	381	441	473	24.1
Other central nervous system (C70, C72)	10	7	7	5	11	57.1
Thyroid (C73)	54	51	48	29	44	–8.3
Other endocrine organs (C74–C75)	20	22	20	24	21	5.0
Hodgkin lymphoma (C81)	44	41	24	20	33	37.5
<i>All lymphomas (C81–C85, C96)</i>	<i>440</i>	<i>517</i>	<i>642</i>	<i>773</i>	<i>693</i>	<i>7.9</i>
Immunoproliferative neoplasms (C88)	3	10	9	8	15	66.7
Myeloma (C90)	161	244	243	284	343	41.2
Lymphoid leukaemia (C91)	116	143	176	173	181	2.8
Myeloid leukaemia (C92–C94)	289	279	354	361	377	6.5
Leukaemia, unspecified (C95)	36	29	14	26	31	121.4
<i>All leukaemias (C91–C95)</i>	<i>441</i>	<i>451</i>	<i>544</i>	<i>560</i>	<i>589</i>	<i>8.3</i>
Polycythaemia rubra vera (D45)	18	25	11	11	12	9.1
Myelodysplastic syndromes and chronic myeloproliferative disorders (D46–D47 ^{(b)(c)})	12	30	103	159	184	78.6
Multiple primary cancers (C97) ^(d)	0	0	0	134	144	—
Unknown primary site (C26, C39, C76–C80)	747	953	1,141	1,242	1,548	35.7
All cancers (C00–C97, D45–D47^(b))	11,197	12,720	14,278	15,323	16,669	16.7

(a) The ICD-10 codes C38.4 and C45 are inseparable in ICD-9 coding (used for deaths registered in 1996 and before).

(b) Only includes D47.1 and D47.3.

(c) The ICD-10 codes D46 and D47 are inseparable in ICD-9 coding (used for deaths registered in 1996 and before).

(d) The ICD-10 code C97 had no equivalent in ICD-9 coding (used for deaths registered in 1996 and before).

Source: National Mortality Database, AIHW.

Table 2.25: Age-standardised death rates for cancer, persons, Australia, selected years 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
NHPA cancers						
Colorectal (C18–C20)	31.7	30.0	28.4	25.8	21.3	–25.0
Lung, bronchus & trachea (C33–C34)	42.5	42.6	39.7	37.6	34.2	–13.9
Melanoma of skin (C43)	4.9	5.4	5.4	5.4	5.6	4.4
Non-Hodgkin lymphoma (C82–C85, C96)	6.9	7.6	8.5	8.5	7.2	–15.3
Other cancers						
Lip (C00)	0.1	0.1	0.1	0.1	0.1	–35.3
Tongue (C01–C02)	1.1	1.2	1.1	0.9	0.9	–19.1
Mouth (C03–C06)	0.8	0.8	0.7	0.7	0.6	–19.5
Major salivary glands (C07–C08)	0.4	0.5	0.4	0.4	0.3	–13.5
Oropharynx (C09–C10)	0.6	0.8	0.8	0.7	0.6	–33.3
Nasopharynx (C11)	0.4	0.4	0.4	0.3	0.2	–36.7
Hypopharynx (C12–C13)	0.4	0.5	0.5	0.3	0.3	–38.2
Pharynx, unspecified (C14)	0.1	0.2	0.2	0.2	0.4	67.1
Nasal cavity, middle ear & sinuses (C30–C31)	0.3	0.2	0.3	0.3	0.2	–45.7
Larynx (C32)	1.5	1.4	1.5	1.1	1.1	–29.2
<i>Head and neck (C01–C14, C30–C32)</i>	5.8	5.9	5.9	4.9	4.5	–24.1
Oesophagus (C15)	4.9	5.7	5.3	5.5	5.5	4.0
Stomach (C16)	12.5	10.2	8.0	6.7	5.7	–28.5
Small intestine (C17)	0.4	0.4	0.4	0.5	0.4	12.5
Colon (C18)	23.6	22.6	21.3	19.1	14.7	–31.0
Rectum (C19–C20)	8.1	7.5	7.1	6.8	6.6	–7.0
Anus (C21)	0.3	0.2	0.2	0.2	0.3	48.5
Liver (C22)	2.6	2.6	3.2	3.5	4.4	38.5
Gallbladder (C23–C24)	2.7	2.3	1.9	2.0	1.4	–26.9
Pancreas (C25)	9.4	9.1	9.4	9.1	9.2	–2.6
Other thoracic organs ex. pleura (C37–C38, ex. C38.4) ^(a)	0.2	0.3	0.2	0.2	0.2	–3.4
Bone & articular cartilage (C40–C41)	0.7	0.6	0.6	0.5	0.5	–17.4
Non-melanoma of skin (C44)	1.9	1.6	2.4	2.0	1.9	–22.9
Mesothelioma and other pleura (C45, C38.4) ^(a)	0.7	0.9	1.2	2.2	2.5	115.0
Kaposi sarcoma (C46)	0.0	0.0	0.0	0.0	0.0	—
Peritoneum & retroperitoneum (C48)	0.3	0.2	0.3	0.4	0.3	–7.1
Other connective and soft tissue (C47, C49)	1.1	1.1	1.3	1.0	0.9	–27.2
Kidney (C64)	4.3	4.4	4.4	4.3	3.9	–11.8
Bladder (C67)	5.1	5.3	5.1	4.5	4.2	–16.9
Other urinary organs (C65–C66, C68)	0.3	0.4	0.3	0.4	0.3	15.1
Eye (C69)	0.2	0.2	0.2	0.2	0.2	–5.4

(continued)

Table 2.25 (continued): Age-standardised death rates for cancer, persons, Australia, selected years 1983–2003

Cancer site/type	1983	1988	1993	1998	2003	Per cent change 93–03
Brain (C71)	5.6	5.7	5.6	5.6	5.5	–2.3
Other central nervous system (C70, C72)	0.2	0.1	0.1	0.1	0.1	4.6
Thyroid (C73)	0.6	0.5	0.5	0.4	0.4	–15.8
Other endocrine organs (C74–C75)	0.3	0.3	0.3	0.3	0.2	–34.0
Hodgkin lymphoma (C81)	0.7	0.7	0.5	0.3	0.3	–34.7
<i>All lymphomas (C81–C85, C96)</i>	<i>7.6</i>	<i>8.3</i>	<i>9.0</i>	<i>8.7</i>	<i>7.5</i>	<i>–16.4</i>
Immunoproliferative neoplasms (C88)	0.2	0.2	0.2	0.2	0.2	–20.3
Myeloma (C90)	2.9	3.4	3.5	3.5	3.6	2.5
Lymphoid leukaemia (C91)	2.4	2.6	2.5	2.3	2.2	–12.4
Myeloid leukaemia (C92–C94)	4.7	4.5	5.0	4.8	4.2	–14.7
Leukaemia, unspecified (C95)	0.6	0.5	0.2	0.3	0.4	76.0
<i>All leukaemias (C91–C95)</i>	<i>7.7</i>	<i>7.6</i>	<i>7.7</i>	<i>7.4</i>	<i>6.8</i>	<i>–11.4</i>
Polycythaemia rubra vera (D45)	0.3	0.3	0.2	0.1	0.1	–27.2
Myelodysplastic syndromes and chronic myeloproliferative disorders (D46–D47 ^{(b)(c)})	0.2	0.5	1.7	2.1	2.1	23.3
Multiple primary cancers (C97) ^(d)	0.0	0.0	0.0	2.0	1.8	—
Unknown primary site (C26, C39, C76–C80)	12.4	14.8	14.7	14.1	15.1	3.0
All cancers (C00–C97, D45–D47^(b))	210.4	212.3	209.6	198.6	184.9	–11.8

(a) The ICD-10 codes C38.4 and C45 are inseparable in ICD-9 coding (used for deaths registered in 1996 and before).

(b) Only includes D47.1 and D47.3.

(c) The ICD-10 codes D46 and D47 are inseparable in ICD-9 coding (used for deaths registered in 1996 and before).

(d) The ICD-10 code C97 had no equivalent in ICD-9 coding (used for deaths registered in 1996 and before).

Source: National Mortality Database, AIHW.

Table 2.26: Age-standardised death rates for cancer, males, Australia, selected years 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
NHPA cancers						
Colorectal (C18–C20)	38.1	37.0	34.6	31.6	26.2	–24.4
Lung, bronchus & trachea (C33–C34)	77.0	73.9	64.3	59.3	49.1	–23.7
Melanoma of skin (C43)	6.0	7.3	8.0	7.7	8.3	3.3
Prostate (C61)	34.7	37.6	43.7	37.2	34.1	–21.9
Non-Hodgkin lymphoma (C82–C85, C96)	8.4	9.5	10.3	9.6	9.0	–13.2
Other cancers						
Lip (C00)	0.3	0.2	0.2	0.1	0.1	–46.3
Tongue (C01–C02)	1.8	1.8	1.5	1.5	1.3	–17.2
Mouth (C03–C06)	1.1	1.1	0.9	0.9	0.7	–13.0
Major salivary glands (C07–C08)	0.8	0.7	0.6	0.6	0.5	–27.0
Oropharynx (C09–C10)	1.1	1.3	1.4	1.1	0.8	–38.7
Nasopharynx (C11)	0.7	0.7	0.6	0.4	0.3	–46.3
Hypopharynx (C12–C13)	0.7	0.9	0.8	0.5	0.5	–30.3
Pharynx, unspecified (C14)	0.1	0.3	0.4	0.3	0.6	77.9
Nasal cavity, middle ear & sinuses (C30–C31)	0.4	0.2	0.4	0.5	0.2	–45.7
Larynx (C32)	3.1	2.8	3.1	2.3	2.1	–33.2
<i>Head and neck (C01–C14, C30–C32)</i>	9.8	9.9	9.6	8.2	7.1	–26.2
Oesophagus (C15)	7.1	8.2	8.0	8.2	8.3	3.3
Stomach (C16)	17.8	15.1	12.1	9.9	7.6	–37.2
Small intestine (C17)	0.6	0.5	0.4	0.7	0.5	46.4
Colon (C18)	26.5	26.2	25.2	22.3	17.4	–30.9
Rectum (C19–C20)	11.6	10.8	9.5	9.3	8.8	–7.2
Anus (C21)	0.2	0.3	0.3	0.2	0.3	23.5
Liver (C22)	4.1	4.0	4.9	5.2	6.5	30.9
Gallbladder (C23–C24)	2.3	1.9	1.7	1.8	1.2	–26.6
Pancreas (C25)	11.9	11.2	10.9	10.4	10.2	–6.2
Other thoracic organs ex. pleura (C37–C38, ex. C38.4) ^(a)	0.2	0.4	0.2	0.1	0.2	–19.7
Bone & articular cartilage (C40–C41)	0.9	0.6	0.7	0.6	0.6	–10.7
Non-melanoma of skin (C44)	3.5	3.0	4.2	3.4	3.0	–27.7
Mesothelioma and other pleura (C45, C38.4) ^(a)	1.3	1.8	2.3	4.6	4.8	110.7
Kaposi sarcoma (C46)	0.0	0.0	0.0	0.0	0.0	—
Peritoneum & retroperitoneum (C48)	0.3	0.2	0.4	0.3	0.1	–76.0
Other connective and soft tissue (C47, C49)	1.4	1.5	1.4	1.2	1.2	–18.7
Breast (C50)	0.3	0.4	0.2	0.2	0.1	–54.9
Penis (C60)	0.3	0.2	0.1	0.1	0.2	14.7
Testis (C62)	0.7	0.5	0.2	0.3	0.2	–5.8

(continued)

Table 2.26 (continued): Age-standardised death rates for cancer, males, Australia, selected years 1983–2003

Cancer site/type	1983	1988	1993	1998	2003	Per cent change 93–03
Other male genital organs (C63)	0.0	0.0	0.0	0.0	0.0	4.9
Kidney (C64)	6.0	5.8	5.5	5.7	5.3	–3.8
Bladder (C67)	9.1	9.6	9.0	7.7	7.0	–22.5
Other urinary organs (C65–C66, C68)	0.4	0.4	0.4	0.5	0.4	3.9
Eye (C69)	0.3	0.3	0.2	0.2	0.2	11.7
Brain (C71)	7.0	7.0	6.9	6.7	6.6	–3.5
Other central nervous system (C70, C72)	0.2	0.2	0.1	0.1	0.1	–17.0
Thyroid (C73)	0.4	0.3	0.4	0.5	0.5	9.2
Other endocrine organs (C74–C75)	0.4	0.3	0.4	0.3	0.2	–51.1
Hodgkin lymphoma (C81)	0.7	1.0	0.8	0.4	0.4	–53.1
<i>All lymphomas (C81–C85, C96)</i>	<i>9.1</i>	<i>10.5</i>	<i>11.1</i>	<i>10.0</i>	<i>9.3</i>	<i>–16.0</i>
Immunoproliferative neoplasms (C88)	0.4	0.3	0.4	0.3	0.2	–43.6
Myeloma (C90)	3.8	3.8	4.6	4.3	4.5	–1.7
Lymphoid leukaemia (C91)	3.4	3.8	3.3	3.1	2.9	–13.4
Myeloid leukaemia (C92–C94)	5.6	5.9	6.4	6.3	5.4	–15.1
Leukaemia, unspecified (C95)	0.8	0.6	0.3	0.5	0.5	71.7
<i>All leukaemias (C91–C95)</i>	<i>9.8</i>	<i>10.3</i>	<i>10.0</i>	<i>9.9</i>	<i>8.8</i>	<i>–11.9</i>
Polycythaemia rubra vera (D45)	0.3	0.3	0.2	0.2	0.2	–30.7
Myelodysplastic syndromes and chronic myeloproliferative disorders (D46–D47 ^{(b)(c)})	0.3	0.7	2.5	3.2	2.9	18.5
Multiple primary cancers (C97) ^(d)	0.0	0.0	0.0	3.1	2.6	—
Unknown primary site (C26, C39, C76–C80)	14.3	18.2	17.1	16.5	17.8	3.8
All cancers (C00–C97, D45–D47^(b))	280.5	283.7	277.2	260.6	236.5	–14.7

(a) The ICD-10 codes C38.4 and C45 are inseparable in ICD-9 coding (used for deaths registered in 1996 and before).

(b) Only includes D47.1 and D47.3.

(c) The ICD-10 codes D46 and D47 are inseparable in ICD-9 coding (used for deaths registered in 1996 and before).

(d) The ICD-10 code C97 had no equivalent in ICD-9 coding (used for deaths registered in 1996 and before).

Source: National Mortality Database, AIHW.

Table 2.27: Age-standardised death rates for cancer, females, Australia, selected years 1983–2003

Cancer site/type (ICD-10 codes)	1983	1988	1993	1998	2003	Per cent change 93–03
NHPA cancers						
Colorectal (C18–C20)	27.2	24.9	23.7	21.3	17.2	–27.3
Lung, bronchus & trachea (C33–C34)	16.7	19.3	20.9	21.0	22.4	6.7
Melanoma of skin (C43)	3.9	3.8	3.2	3.5	3.4	9.1
Breast (C50)	30.2	31.2	30.8	26.4	24.6	–20.0
Cervix (C53)	5.0	4.5	3.7	2.7	2.2	–40.8
Non–Hodgkin lymphoma (C82–C85, C96)	5.8	6.1	7.0	7.6	5.7	–18.5
Other cancers						
Lip (C00)	0.0	0.0	0.0	0.0	0.0	111.7
Tongue (C01–C02)	0.6	0.6	0.6	0.4	0.5	–21.8
Mouth (C03–C06)	0.5	0.5	0.5	0.5	0.4	–24.8
Major salivary glands (C07–C08)	0.3	0.3	0.2	0.2	0.3	13.8
Oropharynx (C09–C10)	0.2	0.3	0.4	0.3	0.3	–15.2
Nasopharynx (C11)	0.2	0.2	0.2	0.2	0.2	–7.5
Hypopharynx (C12–C13)	0.2	0.2	0.2	0.1	0.1	–67.4
Pharynx, unspecified (C14)	0.1	0.1	0.1	0.1	0.1	32.9
Nasal cavity, middle ear & sinuses (C30–C31)	0.2	0.1	0.2	0.2	0.1	–36.2
Larynx (C32)	0.3	0.3	0.3	0.1	0.2	–24.3
<i>Head and neck (C01–C14, C30–C32)</i>	2.4	2.6	2.8	2.1	2.2	–19.6
Oesophagus (C15)	3.1	3.6	3.1	3.2	3.1	–1.2
Stomach (C16)	8.5	6.7	5.0	4.3	4.2	–17.0
Small intestine (C17)	0.3	0.4	0.4	0.3	0.4	–10.5
Colon (C18)	21.5	19.9	18.4	16.5	12.5	–32.3
Rectum (C19–C20)	5.7	5.1	5.3	4.9	4.8	–10.0
Anus (C21)	0.3	0.2	0.1	0.3	0.3	86.3
Liver (C22)	1.5	1.7	1.7	2.1	2.5	53.3
Gallbladder (C23–C24)	3.1	2.5	2.2	2.1	1.5	–28.6
Pancreas (C25)	7.4	7.6	8.1	8.0	8.2	0.0
Other thoracic organs ex. pleura (C37–C38, ex. C38.4) ^(a)	0.1	0.2	0.1	0.1	0.1	–33.1
Bone & articular cartilage (C40–C41)	0.5	0.6	0.5	0.4	0.4	–26.0
Non–melanoma of skin (C44)	1.0	0.7	1.2	1.1	1.0	–11.4
Mesothelioma and other pleura (C45, C38.4) ^(a)	0.2	0.2	0.3	0.5	0.8	199.9
Kaposi sarcoma (C46)	0.0	0.0	0.0	0.0	0.0	—
Peritoneum & retroperitoneum (C48)	0.4	0.2	0.3	0.4	0.5	62.2
Other connective and soft tissue (C47, C49)	0.9	0.9	1.2	0.9	0.7	–39.3
Vulva (C51)	0.5	0.7	0.6	0.6	0.4	–33.1
Vagina (C52)	0.3	0.2	0.3	0.2	0.2	–6.7

(continued)

Table 2.27 (continued): Age-standardised death rates for cancer, females, Australia, selected years 1983–2003

Cancer site/type	1983	1988	1993	1998	2003	Per cent change 93–03
Uterus, body (C54)	2.9	2.5	2.5	2.3	1.9	–22.9
Uterus, unspecified (C55)	0.6	0.4	0.3	0.3	0.7	105.6
Ovary (C56)	8.7	7.8	8.0	7.7	7.1	–12.1
Other female genital organs (C57)	0.2	0.1	0.2	0.3	0.2	2.0
Placenta (C58)	0.0	0.0	0.0	0.0	0.0	–100.0
<i>Gynaecological (C51–C58)</i>	<i>18.2</i>	<i>16.2</i>	<i>15.7</i>	<i>14.1</i>	<i>12.7</i>	<i>–18.7</i>
Kidney (C64)	3.0	3.4	3.6	3.2	2.7	–26.1
Bladder (C67)	2.5	2.6	2.6	2.4	2.3	–12.3
Other urinary organs (C65–C66, C68)	0.3	0.4	0.3	0.3	0.3	28.6
Eye (C69)	0.2	0.2	0.2	0.1	0.2	–19.4
Brain (C71)	4.5	4.6	4.4	4.6	4.4	1.6
Other central nervous system (C70, C72)	0.2	0.1	0.1	0.1	0.1	38.0
Thyroid (C73)	0.8	0.6	0.6	0.3	0.4	–32.9
Other endocrine organs (C74–C75)	0.3	0.3	0.2	0.3	0.2	–10.5
Hodgkin lymphoma (C81)	0.6	0.5	0.3	0.2	0.3	8.9
<i>All lymphomas (C81–C85, C96)</i>	<i>6.4</i>	<i>6.6</i>	<i>7.3</i>	<i>7.8</i>	<i>6.0</i>	<i>–17.5</i>
Immunoproliferative neoplasms (C88)	0.0	0.1	0.1	0.1	0.1	27.8
Myeloma (C90)	2.4	3.1	2.8	2.8	2.9	7.0
Lymphoid leukaemia (C91)	1.7	1.8	2.0	1.7	1.5	–21.4
Myeloid leukaemia (C92–C94)	4.1	3.6	4.0	3.6	3.3	–17.5
Leukaemia, unspecified (C95)	0.5	0.4	0.2	0.3	0.3	76.5
<i>All leukaemias (C91–C95)</i>	<i>6.3</i>	<i>5.8</i>	<i>6.1</i>	<i>5.6</i>	<i>5.1</i>	<i>–16.4</i>
Polycythaemia rubra vera (D45)	0.3	0.3	0.1	0.1	0.1	–12.9
Myelodysplastic syndromes and chronic myeloproliferative disorders (D46–D47 ^{(b)(c)})	0.2	0.4	1.2	1.5	1.5	26.1
Multiple primary cancers (C97) ^(d)	0.0	0.0	0.0	1.3	1.2	—
Unknown primary site (C26, C39, C76–C80)	11.0	12.3	12.9	12.3	13.1	0.9
All cancers (C00–C97, D45–D47^(b))	164.2	164.4	163.7	154.7	146.9	–10.2

(a) The ICD-10 codes C38.4 and C45 are inseparable in ICD-9 coding (used for deaths registered in 1996 and before).

(b) Only includes D47.1 and D47.3.

(c) The ICD-10 codes D46 and D47 are inseparable in ICD-9 coding (used for deaths registered in 1996 and before).

(d) The ICD-10 code C97 had no equivalent in ICD-9 coding (used for deaths registered in 1996 and before).

Source: National Mortality Database, AIHW.

Cancers attributed to smoking and excessive alcohol consumption

Data on cancers attributed to smoking and excessive alcohol consumption are derived from a series of age- and sex-specific aetiological fractions developed by Ridolfo and Stevenson (2001) and from cancer incidence for specific cancer sites for 2003. This methodology and the attributable fractions are described in Appendix B.

Summary

- In 2003 there were an estimated 10,378 new cases of cancer and 7,727 deaths from cancer in Australia attributed to smoking.
- In 2003 there were an estimated 2,844 new cases of cancer and 1,358 deaths from cancer in Australia attributed to excessive alcohol consumption.
- Among the states and territories, the highest incidence and mortality rates attributed to smoking and excessive alcohol consumption were experienced by the Northern Territory. Cancer mortality in the Territory due to smoking was 53% higher than the national rate, while cancer mortality due to excessive alcohol consumption was double the national rate.

Table 2.28: Cancer incidence and mortality attributed to smoking, Australia, 2003

Australia 2003												
	Incidence						Mortality					
	Males		Females		Persons		Males		Females		Persons	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	53	7.0	29	3.7	82	5.3	28	3.7	15	2.0	43	2.8
45-49	185	26.6	72	10.2	257	18.3	102	14.6	38	5.5	140	10.0
50-54	367	56.1	152	23.2	519	39.6	196	29.9	100	15.3	296	22.6
55-59	691	118.2	247	43.3	938	81.2	413	70.6	168	29.4	581	50.3
60-64	874	198.7	361	83.9	1,235	141.9	587	133.6	223	51.8	811	93.1
65-69	1,083	304.4	406	111.1	1,489	206.4	797	224.1	292	79.9	1,089	151.0
70-74	1,354	447.5	506	153.5	1,860	294.2	1,040	343.8	390	118.3	1,430	226.2
75-79	1,289	535.8	627	210.2	1,917	355.5	1,028	427.3	466	156.2	1,495	277.2
80-84	898	616.2	363	164.3	1,262	343.7	747	512.5	332	149.9	1,079	293.9
85 and over	508	564.4	311	158.2	819	285.8	456	506.7	308	156.7	764	266.6
Total	7,302		3,077		10,378		5,394		2,334		7,727	

Rates per 100,000 with 95% confidence intervals (95% CI)

Crude rate	74.0	30.8	52.2	54.6	23.3	38.9
95% CI	72.3 – 75.6	29.7 – 31.9	51.2 – 53.2	53.2 – 56.1	22.4 – 24.3	38.0 – 39.8
AS rate (Aust. 2001)	78.6	27.9	50.8	58.9	20.8	37.8
95% CI	76.8 – 80.5	26.9 – 28.9	49.8 – 51.7	57.3 – 60.5	20.0 – 21.7	36.9 – 38.6
AS rate (WHO World 2000)	54.0	19.6	35.5	39.5	14.2	25.8
95% CI	52.8 – 55.3	18.8 – 20.3	34.8 – 36.2	38.4 – 40.5	13.6 – 14.9	25.2 – 26.4
Risk to age 75	1 in 18	1 in 47	1 in 26	1 in 25	1 in 67	1 in 36
PYLL (0-74)				31,253	12,706	43,959

Average annual numbers and rates by state and territory, 1999-2003

	Incidence						Mortality					
	Males		Females		Persons		Males		Females		Persons	
	Number	AS rate	Number	AS rate	Number	AS rate	Number	AS rate	Number	AS rate	Number	AS rate
NSW	2,482	81.4	1,024	27.9	3,506	51.8	1,878	62.5	770	20.7	2,648	39.1
Vic	1,739	79.2	762	28.2	2,501	50.8	1,346	62.3	588	21.4	1,935	39.2
Qld	1,489	93.0	546	29.8	2,034	58.9	1,037	66.1	381	20.7	1,418	41.3
WA	681	87.3	278	30.1	958	55.9	507	67.0	205	22.1	712	41.9
SA	621	81.4	258	27.3	878	51.1	469	62.2	189	19.5	658	37.9
Tas	219	94.6	97	35.0	316	61.6	162	70.8	72	25.9	234	45.5
ACT	71	67.2	31	23.7	102	42.8	49	48.8	23	18.1	72	31.2
NT	50	99.4	14	36.2	64	70.0	36	82.0	12	31.7	48	58.0

Note: Cancers attributable to smoking are C01-C06, C09-C10, C12-C16, C21.0, C21.1, C25, C32, C33-C34, C51.9, C60, C64, C65, C67.

Source: National Cancer Statistics Clearing House, AIHW.

Table 2.29: Cancer incidence and mortality attributed to excessive alcohol consumption, Australia, 2003

Australia 2003												
Age group	Incidence						Mortality					
	Males		Females		Persons		Males		Females		Persons	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	2	0.2	0	0.1	2	0.2	0	0.1	0	0.0	0	0.0
20-24	1	0.1	3	0.4	4	0.3	0	0.1	0	0.1	1	0.1
25-29	2	0.3	7	1.0	9	0.7	1	0.1	0	0.1	1	0.1
30-34	5	0.7	25	3.3	31	2.0	0	0.0	6	0.7	6	0.4
35-39	12	1.7	59	8.1	71	4.9	8	1.2	9	1.2	17	1.2
40-44	37	4.9	112	14.5	149	9.7	19	2.5	17	2.3	37	2.4
45-49	72	10.4	159	22.5	231	16.5	31	4.4	26	3.7	57	4.1
50-54	122	18.7	203	30.8	325	24.8	60	9.2	42	6.3	102	7.8
55-59	148	25.3	217	38.0	364	31.6	79	13.5	55	9.7	134	11.6
60-64	182	41.4	188	43.5	369	42.4	94	21.4	50	11.6	144	16.6
65-69	173	48.8	185	50.5	358	49.6	119	33.3	62	16.9	181	25.0
70-74	173	57.3	132	39.9	305	48.2	135	44.7	53	16.1	188	29.8
75-79	145	60.2	121	40.5	266	49.3	133	55.1	67	22.4	199	37.0
80-84	88	60.7	123	55.5	211	57.6	81	55.9	73	33.0	155	42.1
85 and over	49	55.0	99	50.5	149	51.9	47	52.2	89	45.2	136	47.4
Total	1,213		1,632		2,844		808		549		1,358	

Rates per 100,000 with 95% confidence intervals (95% CI)

Crude rate	12.3	16.3	14.3	8.2	5.5	6.8
95% CI	11.6 – 13.0	15.5 – 17.1	13.8 – 14.8	7.6 – 8.7	5.0 – 6.0	6.5 – 7.2
AS rate (Aust. 2001)	12.6	15.3	13.9	8.6	4.9	6.6
95% CI	11.9 – 13.3	14.6 – 16.1	13.4 – 14.4	8.0 – 9.2	4.5 – 5.3	6.3 – 7.0
AS rate (WHO World 2000)	9.4	12.1	10.7	6.1	3.5	4.7
95% CI	8.9 – 9.9	11.5 – 12.7	10.3 – 11.1	5.7 – 6.5	3.2 – 3.8	4.5 – 5.0
Risk to age 75	1 in 96	1 in 80	1 in 87	1 in 154	1 in 292	1 in 203
PYLL (0-74)				7,014	5,019	12,032

Average annual numbers and rates by state and territory, 1999-2003

	Incidence						Mortality					
	Males		Females		Persons		Males		Females		Persons	
	Number	AS rate	Number	AS rate	Number	AS rate	Number	AS rate	Number	AS rate	Number	AS rate
NSW	398	12.7	542	15.6	939	14.0	258	8.4	178	4.8	436	6.5
Vic	289	12.8	402	15.7	691	14.2	193	8.8	140	5.2	333	6.8
Qld	224	13.3	290	15.9	514	14.6	140	8.7	86	4.6	226	6.5
WA	109	13.1	146	15.6	256	14.2	64	8.0	43	4.6	107	6.2
SA	86	11.2	134	15.7	220	13.4	61	8.1	44	4.8	106	6.2
Tas	35	14.5	41	15.4	75	14.9	22	9.6	15	5.2	37	7.2
ACT	14	11.9	25	17.3	39	14.5	8	7.8	7	5.2	15	6.3
NT	16	25.0	9	16.7	25	21.1	9	18.0	4	8.6	13	13.4

Note: Cancers attributable to alcohol are C01-C06, C09-C10, C12-C14, C15, C22, C32, C50 (female breast cancer only).

Source: National Cancer Statistics Clearing House, AIHW.